0001171843-22-003647.txt : 20220512 0001171843-22-003647.hdr.sgml : 20220512 20220512171219 ACCESSION NUMBER: 0001171843-22-003647 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RenovaCare, Inc. CENTRAL INDEX KEY: 0001016708 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980170247 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30156 FILM NUMBER: 22918931 BUSINESS ADDRESS: STREET 1: 9375 E. SHEA BLVD. STREET 2: SUITE 107-A CITY: SCOTTSDALE STATE: AZ ZIP: 85260 BUSINESS PHONE: 888-398-0202 MAIL ADDRESS: STREET 1: 9375 E. SHEA BLVD. STREET 2: SUITE 107-A CITY: SCOTTSDALE STATE: AZ ZIP: 85260 FORMER COMPANY: FORMER CONFORMED NAME: Janus Resources, Inc. DATE OF NAME CHANGE: 20110110 FORMER COMPANY: FORMER CONFORMED NAME: ENTHEOS TECHNOLOGIES INC DATE OF NAME CHANGE: 20001002 FORMER COMPANY: FORMER CONFORMED NAME: WHATSONLINE COM INC DATE OF NAME CHANGE: 19990722 10-Q 1 f10q_051022p.htm FORM 10-Q
0001016708 false 12/31 2022 Q1 0001016708 2022-01-01 2022-03-31 0001016708 2022-05-10 0001016708 2022-03-31 0001016708 2021-12-31 0001016708 2021-01-01 2021-03-31 0001016708 us-gaap:CommonStockMember 2021-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001016708 us-gaap:RetainedEarningsMember 2021-12-31 0001016708 us-gaap:CommonStockMember 2020-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001016708 us-gaap:RetainedEarningsMember 2020-12-31 0001016708 2020-12-31 0001016708 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001016708 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001016708 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001016708 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001016708 us-gaap:CommonStockMember 2022-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001016708 us-gaap:RetainedEarningsMember 2022-03-31 0001016708 us-gaap:CommonStockMember 2021-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001016708 us-gaap:RetainedEarningsMember 2021-03-31 0001016708 2021-03-31 0001016708 rcar:AttorneysMember 2022-01-01 2022-03-31 0001016708 rcar:KalenCapitalMember 2022-01-01 2022-03-31 0001016708 rcar:KalenCapitalMember 2022-03-18 0001016708 us-gaap:StockCompensationPlanMember 2022-01-01 2022-03-31 0001016708 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001016708 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001016708 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001016708 rcar:KalenCapitalCorpMember 2022-03-18 0001016708 rcar:KalenCapitalCorpMember 2022-03-01 2022-03-18 0001016708 rcar:SeriesFMember 2022-03-31 0001016708 rcar:SeriesFMember 2021-12-31 0001016708 rcar:SeriesFMember srt:MinimumMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesFMember srt:MaximumMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesGMember 2022-03-31 0001016708 rcar:SeriesGMember 2021-12-31 0001016708 rcar:SeriesGMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesHMember 2022-03-31 0001016708 rcar:SeriesHMember 2021-12-31 0001016708 rcar:SeriesHMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesIMember 2022-03-31 0001016708 rcar:SeriesIMember 2021-12-31 0001016708 rcar:SeriesIMember 2022-01-01 2022-03-31 0001016708 us-gaap:WarrantMember 2022-03-31 0001016708 us-gaap:WarrantMember 2021-12-31 0001016708 2021-01-01 2021-09-30 0001016708 2021-09-30 0001016708 2021-10-01 2022-03-31 0001016708 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001016708 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001016708 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001016708 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001016708 rcar:StemCellSystemsMember 2022-01-01 2022-03-31 0001016708 rcar:StemCellSystemsMember 2021-01-01 2021-03-31 0001016708 rcar:StemCellSystemsMember 2022-03-31 0001016708 us-gaap:SubsequentEventMember rcar:AttorneysMember 2022-04-01 2022-04-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Commission file number 000-30156

 

  RENOVACARE, INC.  
  (Exact name of registrant as specified in its charter)  

 

Nevada   98-0384030
(State or other jurisdiction of incorporation)   (I.R.S. Employer Identification No.)

 

9375 E. Shea Blvd., Suite 107-A

Scottsdale, AZ 85260

  (Address of principal executive offices)  

 

888-398-0202

(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ (Do not check if a smaller reporting company)  
Smaller reporting company ☒ Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act):

Yes ☐ No ☒

 

As of May 10, 2022, the registrant had 87,352,364 shares of its common stock, par value $0.00001 per share, issued and outstanding.

 

 

RENOVACARE, INC.

FORM 10-Q

For The Quarter Ended March 31, 2022

 

TABLE OF CONTENTS

 

    Page #  
PART I - FINANCIAL INFORMATION      
         
Item 1. Financial Statements      
  Consolidated Balance Sheets     1  
  Consolidated Statements of Operations     2  
  Consolidated Statements of Stockholders’ Equity     3  
  Consolidated Statements of Cash Flows     4  
  Notes to Consolidated Financial Statements     5  
           
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations     14  
           
Item 3. Quantitative and Qualitative Disclosures About Market Risk     19  
           
Item 4. Controls and Procedures     19  
           
PART II - OTHER INFORMATION
         
Item 1. Legal Proceedings     19  
           
Item 1A. Risk Factors     19  
           
Item 6. Exhibits     20  
           
Signatures     21  

 

 

 

PART I

 

Item 1. Financial Statements

 

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS        

 

       
   March 31,  December 31,
   2022  2021
ASSETS  (Unaudited)   
Current assets          
Cash  $1,869,865   $2,849,192 
Prepaid expenses   905,997    533,445 
Total current assets   2,775,862    3,382,637 
           
Equipment, net of accumulated depreciation of $15,275 and $12,952, respectively   26,949    29,271 
Intangible assets   152,854    152,854 
Security Deposit   7,995    7,995 
Right of Use Asset   15,866    28,630 
Other Assets   28,997    50,747 
Total assets  $3,008,523   $3,652,134 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
Current liabilities          
Accounts payable and accrued liabilities  $1,369,851   $1,274,748 
Lease liability - current   17,578    30,497 
Total current liabilities   1,387,429    1,305,245 
Convertible promissory note to related party   800,000    - 
Interest payable on convertible promissory note to related party   289    - 
Total liabilities   2,187,718    1,305,245 
           
Commitments and contingencies          
           
Stockholders' equity          
Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding   -    - 
Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at March 31, 2022 and December 31, 2021   874    874 
Additional paid-in capital   36,787,169    36,585,919 
Retained deficit   (35,967,238)   (34,239,904)
Total stockholders' equity   820,805    2,346,889 
Total liabilities and stockholders' equity  $3,008,523   $3,652,134 

 

(See accompanying notes to unaudited consolidated financial statements)

 

 1 

 

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 

 

           
   Three Months Ended
   March 31,
   2022  2021
Revenue  $-   $- 
           
Operating expenses          
Research and development   596,254    1,054,293 
General and administrative   1,146,556    (537,044)
Total operating expenses, net   (1,742,810)   517,249 
Loss from operations        (517,249)
           
Other income          
Interest income   950    7 
Other income   14,815    - 
Interest expense   (289)   - 
Total other income   15,476    7 
Net loss  $(1,727,334)  $(517,242)
           
Basic and Diluted Loss per Common Share  $(0.02)  $(0.01)
           
Weighted average number of common shares outstanding - basic and diluted   87,352,364    87,352,364 

 

(See accompanying notes to unaudited consolidated financial statements)

 

 

 

 

 2 

 

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)             

 

                          
FOR THE THREE MONTHS ENDED MARCH 31, 2022  Common Stock  Additional
Paid-in		  Retained  Total
Stockholders'
   Shares  Amount  Capital  Deficit  Equity
Balance, December 31, 2021   87,352,364   $874   $36,585,919   $(34,239,904)  $2,346,889 
Stock based compensation due to common stock purchase options   -    -    201,250    -    201,250 
Net loss for the three months ended March 31, 2022   -    -    -    (1,727,334)   (1,727,334)
Balance, March 31, 2022   87,352,364    874    36,787,169    (35,967,238)   820,805 
                          
FOR THE THREE MONTHS ENDED MARCH 31, 2021                         
                          
Balance, December 31, 2020   87,352,364   $874   $36,846,082   $(29,768,181)  $7,078,775 
Stock based compensation due to common stock purchase options   -    -    352,063    -    352,063 
Reversal of stock-based compensation due to common stock purchase option cancellations   -    -    (1,248,575)   -    (1,248,575)
Net loss for the three months ended March 31, 2021   -    -    -    (517,242)   (517,242)
Balance, March 31, 2021   87,352,364    874    35,949,570    (30,285,423)   5,665,021 

 

(See accompanying notes to unaudited consolidated financial statements)

 

 3 

 

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

         

 

           
   Three Months Ended
   March 31,
   2022  2021
Cash flows used in operating activities          
Net loss  $(1,727,334)  $(517,242)
Adjustments to reconcile net loss to net cash flows used in operating activities          
Depreciation expense   2,322    2,324 
Stock based compensation expense   223,000    (874,760)
Non cash lease expense   (155)   1,649 
Changes in operating assets and liabilities:          
(Increase) decrease in prepaid expenses and other assets   (372,552)   104,104 
Increase (decrease) in accounts payable   95,103    (521,199)
Increase (decrease) in related party interest payable   289    - 
Net cash flows used in operating activities   (1,779,327)   (1,805,124)
           
Cash flows from financing activities          
Proceeds from the issuance of a related party convertible promissory note   800,000    - 
Net cash flows from financing activities   800,000    - 
Decrease in cash   (979,327)   (1,805,124)
Cash at beginning of period   2,849,192    7,412,969 
Cash at end of period  $1,869,865   $5,607,845 

 

 

(See accompanying notes to unaudited consolidated financial statements)

 4 

 

RENOVACARE, INC. AND SUBSIDIARY

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1. Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share

 

Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (“RenovaCare” or the “Company”) as of March 31, 2022, and for the three months ended March 31, 2022 and 2021 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for  quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.

 

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2022, results of operations and stockholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 

Organization

 

RenovaCare, Inc., formerly Janus Resources, is a Nevada corporation. RenovaCare, Inc. was incorporated under the laws of the State of Utah on July 14, 1983 as Far West Gold, Inc.

 

The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of March 31, 2022, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.

 

RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.

 

On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”). The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the “SkinGunTM”) as a cell therapy onto wounds including burns to facilitate healing.

 

Currently, the Company’s proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Liechtenstein, and the United Kingdom. The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.

 

The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

 

 5 

 

Going Concern

 

The Company has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. At March 31, 2022, the Company had approximately $1,870,000 in cash on hand, current liabilities of $1,387,429 and an accumulated deficit of $35,967,238. The Company has historically funded its operations through the issuance of convertible notes, the sale of common stock and issuance of warrants.

 

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans, which are subject to change, management believes that the Company’s existing cash as of March 31, 2022 is insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.

 

The Company is responsible to bear the costs to defend itself and its directors and officers, pursuant to the indemnification clause in the Company’s bylaws, against various Lawsuits (as defined in “Note 7. Commitments and Contingencies—Legal Proceedings” below) currently consisting of a civil action filed by the SEC and two class actions and three derivative actions. See “Note 7. Commitments and Contingencies—Legal Proceedings.” The legal costs to defend the Company against the Lawsuits are expected to be material. During the three months ended March 31, 2022, the Company made legal retainer payments totaling $1,180,000 and incurred $864,000 in legal costs related to the Lawsuits. To assist the Company in paying the costs to defend against the Lawsuits, Kalen Capital Corporation, an Alberta Canada corporation (“Kalen Capital”) which is wholly-owned by the Mr. Harmel S. Rayat (“Mr. Rayat”), the Company’s President, Chief Executive Officer and Chairman, loaned the Company $800,000 on March 18, 2022, as evidenced by the Unsecured Note (as defined in “Note 3. Related Party Convertible Promissory Note” below). Due to the nature and early stage of the Lawsuits, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.

 

The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The future of the Company will depend on its ability to successfully raise capital from external sources. As noted above, management believes that the Company’s existing cash as of March 31, 2022 are insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future product development and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Debt financing may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of the Company’s assets.

 

Accounting Pronouncements

 

The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Consolidated Financial Statements.

 

 

 
 6 

 

New Accounting Pronouncements Not Yet Adopted

 

None.

 

Accounting Pronouncements Recently Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40),” to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly changed the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. For smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard on January 1, 2022, with no impact to its financial statements.

 

Earnings (Loss) Per Share

 

The Company presents both basic and diluted earnings per share ("EPS"). Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants or stock options on net loss per share because to do so would be antidilutive.

 

Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2022 and 2021:

 

          
   Three Months Ended
   March 31,
   2022  2021
Basic and Diluted EPS Computation          
Numerator:          
Loss available to common stockholders'  $(1,727,334)  $(517,242)
Denominator:          
Weighted average number of common shares outstanding   87,352,364    87,352,364 
Basic and diluted EPS  $(0.02)  $(0.01)
           
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:          
Stock options   3,099,999    3,164,999 
Warrants   11,705,250    12,296,912 
Total shares not included in the computation of diluted losses per share   14,805,249    15,461,911 

 

 

 

 

 

 

 
 7 

 

Note 2. Prepaid Expenses

 

Prepaid expenses and other current assets consist of the following:

 

Schedule of prepaid expenses and other current assets          
   March 31,  December 31,
   2022  2021
Prepaid stock options for services   87,000    87,001 
Prepaid professional fees   626,126    100,930 
Prepaid research and development expense   173,124    289,746 
Other prepaid costs   19,747    13,964 
Refunds due   -    41,804 
Total prepaid expenses  $905,997   $533,445 

 

Note 3. Related Party Convertible Promissory Note

 

On March 18, 2022, the Company issued an Unsecured Convertible Promissory Note (the “Unsecured Note”) to Kalen Capital. Pursuant to the terms of the Unsecured Note, Kalen Capital loaned the Company $800,000 at an annual interest rate of 1% per year, compounded daily. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Unsecured Note, and any balance thereunder, automatically converts into securities of the Company upon receipt of an equity financing from third-party(s) of not less than ten million dollars ($10,000,000) at a conversion price equal to 80% of the price paid in such a financing. Also, after June 23, 2023, Kalen Capital may convert all or any portion of the balance into shares of common stock at a conversion price of $0.45 per share, representing a fifty 50% percent premium to the closing price of the Company’s common stock on March 17, 2022. There is no commitment from Kalen Capital for any additional funding.

 

During the three months ended March 31, 2022, the Company recognized $289 of interest expense.

 

Note 4. Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued expenses consists of the following:

          
  

March 31,

   2022  2021
Legal fees and related  $1,176,033   $869,950 
Officer compensation   -    55,040 
Consultants   5,679    117,943 
Trade payables   188,139    231,815 
Total  $1,369,851   $1,274,748 

 

Note 5. Equity

 

Common Stock

 

At March 31, 2022, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share and 87,352,364 shares of common stock outstanding.

 

 8 

 

Warrants

 

The Company has issued warrants to purchase common stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information about warrants outstanding at March 31, 2022 and December 31, 2020:

 

                  
   Shares of Common Stock Issuable from
Warrants Outstanding as of		  Weighted   
   March 31,  December 31,  Average   
Description  2022  2021  Exercise Price  Expiration
Series F   -    7,246   $3.45   February 23, 2022 & March 9, 2022
Series G   460,250    460,250   $2.68   July 21, 2022
Series H   910,000    910,000   $2.75   October 16, 2022
Series I   10,335,000    10,335,000   $2.00   November 26, 2025
Total   11,705,250    12,296,912         

 

During the three months ended March 31, 2022, all the Series F Warrants expired unexercised.

 

Stock Options

 

The following table summarizes stock option activity for the three months ended March 31, 2022:

 

                    
   Number of
Options		  Weighted
Average
Exercise
Price ($)		  Weighted
Average
Remaining
Contractual
Term
(years)		  Aggregate
Intrinsic
Value ($)
Outstanding at December 31, 2020   5,895,570    2.45           
Granted   50,000    1.72           
Forfeited   (2,805,571)   2.74           
Outstanding at September 30, 2021   3,139,999    2.17           
Forfeited   (40,000)   1.79           
Outstanding at March 31, 2022   3,099,999    2.17    4.30    - 
Vested and exercisable at March 31, 2022   2,699,999    2.02    4.30    - 

 

The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three months ended March 31, 2022 and 2021:

 

          
   Three Months Ended March 31,
   2022  2021
Research and development  $217,500   $278,815 
General and administrative   5,500    (1,153,575)
Total  $223,000   $(874,760)

 

Note 6. Leases

 

In February 2020, the Company entered into a two-year lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey (the “Premises”). Monthly base rent in year one of the lease is $4,356; and $4,459 in year 2 of the lease. The term (and payment of the monthly rent) commenced upon completion of the landlord’s work on August 1, 2020. The Company vacated the premises in May of 2021 and relocated its corporate offices to 9375 E. Shea Blvd., Suite 107-A, Scottsdale, AZ 85260.

 

The Company’s existing lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s.

 

 9 

 

As of March 31, 2022, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations.

 

The Company does not have any finance leases.

 

 Supplemental lease information:

 

      
   As of March 31,  As of December 31,
   2022  2021
Operating lease right-of-use asset  $15,866   $28,630 
           
Current maturities of operating lease  $17,578   $30,497 
Current maturities of operating lease in accounts payable   8,918    - 
Total operating lease liabilities  $26,496   $30,497 
           
           
Weighted Average remaining lease term (in years):   0.34    0.58 
Right-of-use asset obtained in exchange for lease obligation   -   $

98,405

 

 

Supplemental information for the three months ended March 31, 2022 and 2021:

 

   2022  2021
Cash paid for amount included in the measurement of lease liabilities for operating lease  $4,459   $13,068 

 

The Company leases office space under a non-cancellable operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at March 31, 2022 for future periods are as follows:

 

     
2022   26,754 
Total future minimum lease payments   26,754 
Less imputed interest   (538)
Total  $26,216 

 

Note 7. Commitments and Contingencies

 

Stem Cell Systems

 

In connection with the Company’s anticipated future regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with medical device prototypes and related design documents and data under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&D Agreement (the “Strategic Agreement”) having an initial term of three years with successive one-year extensions unless earlier terminated. The Strategic Agreement includes a $39,000 monthly fee to be paid to StemCell Systems along with any additional expenses incurred. The Company, StemCell Systems and certain affiliates of StemCell Systems entered into a Rights of First Refusal and Corporate Opportunities Agreement (the “ROFR Agreement”). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Company’s acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of $125,931 and $120,377 during the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the Company had a balance due to StemCell Systems of $83,700. On April 28, 2022 the Company provided StemCell Systems with notice of termination of the Strategic Agreement. See “Note 8. Subsequent Events.”

 10 

 

Legal Proceedings

 

SEC Civil Complaint

 

On May 28, 2021 the SEC filed a civil complaint (the “SEC Action”), in the United States District Court for the Southern District of New York, naming the Company and Harmel S. Rayat, the Company’s current President, Chief Executive Officer, Chief Financial Officer and Sole Director as defendants (the “Defendants”). The SEC Action alleges among other things that Mr. Rayat and the Company with violated the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also alleges that Mr. Rayat aided and abetted the violations of those provisions by the Company. The SEC Action also alleges that the Company violated the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks, among other relief, permanent injunctions and civil penalties against the Defendants, and officer-and-director and penny stock bars against Mr. Rayat. On August 31, 2021 the Defendants filed an answer to the Complaint. On September 21, 2021, the SEC filed a motion to strike Defendants equitable affirmative defenses which motion was granted by the court on October 18, 2021. The Company continues to defend itself and the named individuals against the allegations set forth in the SEC Action. Due to the nature and early stage of the SEC Action, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.

 

Class Action Complaints

 

On July 16, 2021, Gabrielle A. Boller filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the “Boller Lawsuit”), against the Company and certain past and current officers and members of the Company’s board of directors (collectively, the “Boller Defendants”). The Boller Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the SEC Action, the Boller Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Boller Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred in the Boller Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.

 

The Company disputes the plaintiffs’ claims in the Boller Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Boller Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

On July 21, 2021, Michael Solakian, filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the “Solakian Lawsuit”), against the Company and certain past and current officers and members of the Company’s board of directors (collectively, the “Solakian Defendants”). The Solakian Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the SEC Action, the Solakian Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Solakian Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred in the Solakian Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.

 

The Company disputes the plaintiffs’ claims in the Solakian Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Solakian Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

 

 
 11 

 

Shareholder Derivative Complaints

 

On December 20, 2021, Melvin Emberland (“Emberland”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “Emberland Lawsuit”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “Emberland Defendants”). In the complaint, Emberland’s allegations, relating to the facts and circumstances underlying the allegations in the SEC Action include, but are not limited to (i) breach of fiduciary duties by the individual Emberland Defendants, (ii) unjust enrichment and (iii) violation of Section 10(b) and 21D of the Securities Exchange Act of 1934. Emberland did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Emberland seeks (i) a declaration that the Emberland Defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company, (ii) a determination awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Emberland Defendants, (iii) a directive to the Company and the Emberland Defendants to take all necessary actions to reform and improve the Company’s corporate governance and internal procedures to comply with applicable laws, and (iv) Plaintiff is seeking, among other things, restitution from the individual Emberland Defendants and disgorgement of profits, benefits and other compensation obtained by such Emberland Defendants, costs and disbursements of the action including reasonable attorney’s fees, accountants’ and expert fees and expenses, an order directing the taking of certain corporate actions relating to its board of directors and corporate governance.

 

The Company disputes Emberland’s claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Emberland Defendants. Given the uncertainty of litigation, the preliminary stage of the Emberland Lawsuit, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

On January 6, 2022, Zoser Vargas (“Vargas”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “Vargas Lawsuit”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “Vargas Defendants”). In the complaint Vargas’ allegations relating to the facts and circumstances underlying the allegations in the SEC Action include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the Vargas Defendants’ breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Vargas Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Vargas Defendants.

 

The Company disputes Vargas’ claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Vargas Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

On January 28, 2022, Aviva Meyer (“Meyer”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “Meyer Lawsuit”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “Meyer Defendants”). In the complaint Meyer’s allegations relating to the facts and circumstances underlying the allegations in the SEC Action include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the Vargas Defendants’ breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Meyer Defendants.

 

 12 

 

The Company disputes Meyer’s claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Meyer Defendants Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

The Company believes that the claims asserted in the SEC Action, the Boller Lawsuit, the Solakian Lawsuit, the Emberland Lawsuit, the Vargas Lawsuit, and the Meyer Lawsuit (collectively, the “Lawsuits”) are without merit and intends to vigorously defend each Lawsuit.

 

Note 8. Subsequent Events

 

Management has reviewed material events subsequent of the period ended March 31, 2022 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

 

On April 21, 2022, the Company made retainer payments to its attorneys in the amount of $1,180,000.

 

On April 28, 2022, the Company terminated the Strategic Agreement with StemCell Systems.

 

 13 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward-Looking Statements

 

This discussion and analysis of financial condition and results of operations is based upon and should be read in conjunction with the unaudited interim consolidated financial statements of RenovaCare, Inc. (“RenovaCare”) and its wholly-owned subsidiary (collectively with RenovaCare, “we,” “our,” “us,” or the “Company”), appearing elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis the Company reviews its estimates and assumptions. The estimates were based on historical experience and other assumptions that the Company believes to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Critical accounting policies, the policies the Company believes are most important to the presentation of its financial statements and require the most difficult, subjective and complex judgments, are outlined below in “Critical Accounting Policies,” and have not changed significantly since 2020.

 

This Quarterly Report on Form 10-Q also contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information relating to the Company that is based on management's exercise of business judgment and assumptions made by and information currently available to management. Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. When used in this document and other documents, releases and reports released by us, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “the facts suggest” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward-looking statements and unknown, unidentified or unpredictable factors could materially and adversely impact our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Several of these factors include, without limitation:

 

  · our ability to meet requisite regulations or receive regulatory approvals in the United States, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States and abroad;
  · new entrance of competitive products or further penetration of existing products in our markets;
  · results of our clinical trials;
  · failure of our products to gain market acceptance;
  · the cost and success of our development programs;
  · our failure to obtain financing as, if and when needed, on commercially acceptable terms;
  · our failure to attract and retain qualified personnel;
  · our failure to adequately manage our growth and expansion;
  · the effect on us from adverse publicity related to our products or the Company itself; and
  · our failure to defend against any adverse claims relating to our intellectual property.

 

 14 

 

The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by us. The reader is cautioned that no statements contained in this Form 10-Q should be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks described in this report and matters described in this report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur.

 

Overview

 

We are a development-stage biotechnology and medical device company focusing on the research, development and commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities, business development efforts, and raising capital to support such activities.

  

The Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., owns the CellMist™ System which is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically with our SkinGun™ spray device as a cell therapy onto wounds including burns to facilitate healing. The CellMist™ System also includes our unique, closed, automated cell isolation device (the “CID”) to harvest stem cells from tissues which is in prototype development.

 

Currently, our proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Lichtenstein, and the United Kingdom. The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.

 

In May 2021, the Company announced that the US Food and Drug Administration (FDA) fully approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial, designated CELLMIST 1, designed to evaluate the safety and feasibility of autologous skin and pluripotent stem cells rendered by its manual CellMist™ System from donor skin and applied topically with the electronic SkinGun™ spray device for treatment of acute burn wounds. The clinical trial protocol is an open-label, single-arm clinical study designated to enroll 14 adult human burn subjects with partial-thickness, second-degree deep thermal burn wounds covering between 10% and 30% total body surface area. The Company may engage up to four (4) U.S. burn centers to conduct the clinical study.

 

During the three months ended March 31, 2022, the Board decided to stop enrollment of patients into the clinical trial and take other measures to reduce the Company’s overhead in an effort to conserve financial resources as it continues to defend against the Lawsuits; however, medical evaluation of the treated subjects will continue periodically as scheduled in the clinical protocol at the clinical study site until October 2022, when the study concludes. The Company hopes to restart the clinical trial at a future date upon the occurrence of a favorable outcome against the Lawsuits and additional financing. 

 

Research, development and commercialization of new technologies generally requires significant financial resources, involves a high degree of risk, and there is no assurance that development activities will result in a commercially viable product. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and defends itself against the Lawsuits (as defined in “Part 2-Other Information, Item 1. Legal Proceedings”). The Company will need to raise additional capital through partnerships or the sale of securities to accomplish its business plan. Failing to secure such additional funding poses a significant risk. The Company's ability to meet its financial obligations, including to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

 

 15 

 

Components of Our Results of Operations

 

Revenue

 

To date we have not generated any product revenues and do not expect to generate any revenue for the foreseeable future. Our ability to generate revenue and become profitable depends upon our ability to obtain marketing approval and successfully commercialization of our CellMistTM System.

 

Operating Expenses

 

Research and Development

 

Research and development (“R&D”) expenses consist primarily of costs incurred for the development of our CellMistTM System and include:

 

  · design, pilot-scale manufacturing and pre-clinical testing of our cell isolation and SkinGunTM spray devices.
  · employee-related expenses associated with our research and development activities, including salaries, benefits, travel and non-cash stock-based compensation expenses.
  ·

costs associated with quality management systems including device verification and validation testing, and regulatory operations and regulatory compliance.

  · expenses incurred under agreements related to our clinical trial.
  · other research and development costs including contract consulting fees and non-cash stock-based compensation to contract research organizations (CROs) and other third parties.

 

We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our CellMistTM System. In the future, we expect that research and development expenses will increase due to our ongoing product development and approval efforts. We expense research and development costs as incurred.

 

General and Administrative

 

General and administrative expenses consist primarily of personnel costs, including non-cash stock-based compensation related to directors and employees, professional service costs including legal, accounting, and other consulting fees and other general and administrative expenses including investor relations, insurance, and facilities costs. We expect general and administrative expenses to increase in the future as we hire personnel and incur additional costs to support the expansion of our research and development activities, our operation as a public company and to defend against the Lawsuits.

 

Stock-Based Compensation

 

Expense associated with equity-based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules and is non-cash in nature. Stock compensation represents the expense associated with the amortization of our stock options.

 

Other Income (Expense)

 

Other expense consists of the interest payable under our convertible note. Other income consists of interest income earned on our cash and cash equivalents and the reimbursement of legal fees from our Directors & Officers insurance policy.

 

Income Taxes

 

We have yet to generate taxable income. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $21,945,000 as of December 31, 2021. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes until we have taxable income after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses.

 

 16 

 

Results of Operations

 

Comparison of Three Months Ended March 31, 2022 and 2021

 

Research and Development Expenses

 

   Three Months Ended March 31,  Increase /
   2022  2021  (Decrease)
Manufacturing clinical supplies(1)  $13,719   $216,183   $(202,464)
Personnel related(2)   117,873    154,175    (36,302)
Stock-based compensation(3)   217,500    278,813    (61,313)
Clinical trials(4)   153,715    306,356    (152,641)
Regulatory(5)   4,716    9,832    (5,116)
All other(5)   88,731    88,934    (203)
   $596,254   $1,054,293   $(458,039)

 

(1)Manufacturing clinical supplies decreased due to completion of the pilot-scale manufacturing and validation testing of the components of the CellMist™ System and the electronic SkinGun™ spray device to be used in our clinical trials which mostly tailed off during the quarters ended March 31, 2021.
(2)Personnel related expenses decreased primarily due to the absence of a bonus paid to our Chief Science Officer during the three months ended March 31, 2021.
(3)Stock compensation expense decreased due primarily to the completion of vesting in 2021 of prior issued stock options.
(4)In 2020 and early 2021, the Company’s incurred certain costs in preparation for its clinical trial during which time the set-up costs were mostly completed with future clinical trial costs expected to fluctuate depending on the number of enrollees into the clinical trial. During the three months ended March 31, 2022 compared to the same period in 2021, clinical trial expenses decreased primarily due to the completion of the set-up costs and subsequent enrollment of only two patients. As a result of the decision during Q1 to stop enrollment, the Company expects clinical trial expenses to decrease moving forward.
(5)All other expenses relate primarily to the prototype development of the electronic SkinGun ™ at StemCell Systems. These costs are expected to decrease as a result of the Company’s, April 28, 2022 notice to terminate the Strategic R&D Agreement.

 

 17 

 

General and Administrative Expenses

 

   Three Months Ended March 31,  Increase /
   2022  2021  (Decrease)
Personnel related(1)  $129,311   $208,684   $(79,373)
Stock-based compensation(2)   5,500    (1,153,575)   1,159,075 
Professional and consultant fees(3)   985,957    283,791    702,166 
All other(4)   25,788    124,056    (98,268)
Total G&A Expense  $1,146,556   $(537,044)  $1,683,600 

 

(1)Personnel related costs are expected to decrease slightly due to lower headcount starting mid-year 2021.
(2)Stock compensation expense in 2021 decreased due to the forfeiture and cancellation of 2,730,571 stock options as a result of the resignation of the Company’s former Chairman, President and Chief Executive Officer and two members of the Company’s Board of Directors Compensation expense was recorded on these options prior to their full vesting. As a result, the Company recognized a $1,248,575 reversal of the prior recognized compensation expense related to the cancelled options.
(3)Professional and consultant fees increased primarily due an increase in legal fees related to the Lawsuits. During the three months ended March 31, 2022, the Company incurred $49,267 in fees related to our patents and trademarks, $863,940 in legal fees related to the Lawsuits, $29,000 related to the preparation and audit of our financial statements and related filings with the SEC, and $43,750 for other legal related costs. The Company is obligated, pursuant to its bylaws, to indemnify its directors and officers. As a result, all legal costs related to the Lawsuits are recorded to the books of the Company. Insurance proceeds to cover the cost of the Company’s defense against the Lawsuits is recorded to other income at the time of receipt.
(4)All other costs decreased primarily due to the absence of expense related to directors’ and officers’ insurance and, to a lesser extent, a decrease in investor relations activities.

 

Liquidity and Capital Resources

 

The Company does not have any commercialized products, has not generated any meaningful revenue since inception and has sustained recurring losses and negative cash flows since inception. During the three months ended March 31, 2022 and 2021, the Company has incurred operating losses of $1,743,000 and $517,000, respectively and has used cash in operating activities of $1,779,000 and $1,805,000, respectively. The Company expects to incur losses as it continues to fund its legal defense and scaled-back development of its products and technologies.

 

At March 31, 2022, the Company had current and total liabilities of $1,387,000 and $2,188,000, respectively, including $1,176,000 of current liabilities related to its defense against the Lawsuits compared to $2,776,000 of current assets. As of March 31, 2022, the Company’s working capital totaled $1,388,433 not including approximately $1,042,000 in proceeds expected to be realized under its D&O Policy with AIG. In order to preserve its cash resources, the Company has taken measures to streamline operations, including ending enrollment of patients into its clinical trial, renegotiating and terminating certain agreements and service arrangements and entered into a loan agreement with Kalen Capital Corporation, an Alberta Canada corporation (“Kalen Capital”) which is wholly-owned by the Mr. Harmel S. Rayat, the Company’s President, Chief Executive Officer and Chairman, for $800,000 on March 18, 2022. As a result of the actions taken, the Company is in an improved position to maintain its solvency. However, due to the nature and early stage of the Lawsuits, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense. As a result, the Company estimates cash on hand will be insufficient for the twelve months following the date these financial statements are issued.

 

Historically, the Company has been funded through the sale of equity securities and debt financings. The future of the Company will depend on its ability to successfully raise capital from external sources to fund operations. If the Company is unable to obtain adequate funds, or if such funds are not available to it on acceptable terms, the Company's ability to continue its business to develop its cellular therapies will be significantly impaired and it may cause the Company to curtail operations. Although the Company has instituted cost savings measures, it will continue to assess its ongoing expenses.

 

Fair Value of Financial Instruments and Risks

 

The carrying value of cash, accounts payable and interest payable approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

 

 

 18 

 

Market Risk Disclosures

 

We have not entered into derivative contracts either to hedge existing risks or for speculative purposes during the three months ended March 31, 2022 or year ended December 31, 2021, and the subsequent period through the date of this report.

 

Off-Balance Sheet Arrangements and Contractual Obligations

 

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of March 31, 2022, we were not involved in any SPE transactions. 

 

Recently Accounting Standards

 

See Note 1 to our Consolidated Financial Statements for more information regarding recent accounting standards and their impact to our consolidated results of operations and financial position.

 

Transactions with Related Persons

 

None.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments for trading purposes.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Interim Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on this evaluation, our Interim Chief Executive Officer and Interim Chief Financial Officer concluded that as of March 31, 2022, that our disclosure controls and procedures were effective such that the information required to be disclosed in our SEC filings is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we are involved in litigation and other proceedings, including matters related to intellectual property and regulatory claims. See Note 7 to our unaudited consolidated financial statements for information on certain legal proceedings, which is incorporated by reference herein.

 

 19 

 

Item 1A. Risk Factors

 

Our results of operations and financial condition could be adversely affected by numerous risks. In addition to the other information in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for Fiscal 2021. These are not the only risks and uncertainties facing us. Additional risks not currently known to us or that we currently believe are immaterial may also negatively impact our business, financial condition, results of operations and future prospects.

 

Item 6. Exhibits

 

Exhibit No.   Description of Exhibit
31.1   Certification of the Principal Executive Officer  and Principal Financial Officer pursuant to Rule 13a-14(a).*
32.1   Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
     
101.INS   Inline XBRL Instance Document**
101.SCH   Inline XBRL Taxonomy Extension - Schema Document**
101.CAL   Inline XBRL Taxonomy Extension - Calculation Linkbase Document**
101.DEF   Inline XBRL Taxonomy Extension - Definition Linkbase Document**
101.LAB   Inline XBRL Taxonomy Extension - Label Linkbase Document**
101.PRE   Inline XBRL Taxonomy Extension - Presentation Linkbase Document**
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
           

_______________

* Filed herewith.
** Furnished herewith. iXBRL (Inline eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 20 

 

SIGNATURES

 

Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

RenovaCare, Inc.

(Registrant)

 

      
Date: May 12, 2022By: /s/ Harmel S. Rayat
   Name: Harmel S. Rayat
   Title: Interim President & Chief Executive Officer, and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

 

 

 

 

21

 

 EX-31.1 2 exh_311.htm EXHIBIT 31.1

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Harmel S. Rayat, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of RenovaCare, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

      
Date: May 12, 2022By: /s/ Harmel S. Rayat
   Name: Harmel S. Rayat
   Title: Interim President & Chief Executive Officer, and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
 EX-32.1 3 exh_321.htm EXHIBIT 32.1

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

The undersigned, as the Interim Chief Executive Officer and the Interim Chief Financial Officer of RenovaCare, Inc., respectively, certifies that, to the best of their knowledge and belief, the Quarterly Report on Form 10-Q for the three months ended March 31, 2022 that accompanies this certification fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of RenovaCare, Inc. at the dates and for the periods indicated. The foregoing certification is made pursuant to 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and shall not be relied upon for any other purpose.

 

      
Date: May 12, 2022By: /s/ Harmel S. Rayat
   Name: Harmel S. Rayat
   Title: Interim President & Chief Executive Officer, and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

 

 EX-101.SCH 4 rcar-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Convertible Promissory Note link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Party Convertible Promissory Note (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 rcar-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 rcar-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 rcar-20220331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Counterparty Name [Axis] Attorneys [Member] Related Party [Axis] Kalen Capital [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement [Member] Warrant [Member] Kalen Capital Corp [Member] Class of Warrant or Right [Axis] Series F [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Series G [Member] Series H [Member] Series I [Member] Income Statement Location [Axis] Research and Development Expense [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] General and Administrative Expense [Member] StemCell Systems [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash Prepaid expenses Total current assets Equipment, net of accumulated depreciation of $15,275 and $12,952, respectively Intangible assets Security Deposit Right of Use Asset Other Assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Lease liability - current Total current liabilities Convertible promissory note to related party Interest payable on convertible promissory note to related party Total liabilities Commitments and contingencies Stockholders' equity Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at March 31, 2022 and December 31, 2021 Additional paid-in capital Retained deficit Total stockholders' equity Total liabilities and stockholders' equity Accumulated depreciation Preferred stock, par value Preferred stock, Authorized Preferred stock, shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, Authorized Common stock, shares Issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses Research and development General and administrative Total operating expenses, net Loss from operations Other income Interest income Other income Interest expense Total other income Net loss Basic and Diluted Loss per Common Share Weighted average number of common shares outstanding - basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Stock based compensation due to common stock purchase options Reversal of stock-based compensation due to common stock purchase option cancellations Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows used in operating activities Net loss Adjustments to reconcile net loss to net cash flows used in operating activities Depreciation expense Stock based compensation expense Non cash lease expense Changes in operating assets and liabilities: (Increase) decrease in prepaid expenses and other assets Increase (decrease) in accounts payable Increase (decrease) in related party interest payable Net cash flows used in operating activities Cash flows from financing activities Proceeds from the issuance of a related party convertible promissory note Net cash flows from financing activities Decrease in cash Cash at beginning of period Cash at end of period Accounting Policies [Abstract] Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share Prepaid Expenses Prepaid Expenses Related Party Convertible Promissory Note Related Party Convertible Promissory Note Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Equity [Abstract] Equity Leases [Abstract] Leases Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation Organization Going Concern Accounting Pronouncements Earnings (Loss) Per Share Schedule of computation of basic and diluted net loss per share Prepaid Expenses Schedule of accounts payable and accrued expenses Schedule of warrants outstanding Schedule of stock option activity Condensed Income Statement [Table Text Block] Schedule of supplemental lease information Schedule of future lease payments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' Denominator: Weighted average number of common shares outstanding Basic and diluted EPS The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Total shares not included in the computation of diluted losses per share Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Date of Incorporation Cash on hand Current liability Accumulated deficit Payments to retainer Legal Fees Loan Prepaid stock options for services Prepaid professional fees Prepaid research and development expense Other prepaid costs Refunds due Total prepaid expenses Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Interest rate Conversion price Interest expense Legal fees and related Officer compensation Consultants Trade payables Total Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Shares of Common Stock Issuable from Warrants Outstanding Weighted Average Exercise Price Expiration Options outstanding - beginning balance Options outstanding - beginning balance Options granted Options granted Options forfeited Options forfeited Options oustanding - ending balance Options outstanding - ending balance Weighted average remaining contracted term Aggregate intrinsic value Options Vested and Exercisable Options Vested and Exercisable Options Vested and Exercisable Options Vested and Exercisable Total Operating lease right-of-use asset Current maturities of operating lease Current maturities of operating lease in accounts payable Total operating lease liabilities Weighted Average remaining lease term (in years): Right-of-use asset obtained in exchange for lease obligation Cash paid for amount included in the measurement of lease liabilities for operating lease 2022 Total future minimum lease payments Less imputed interest Total Base rent for First year Base rent for Second year Lease term Periodic Payment Incurred expenses Due to related party Subsequent Event [Table] Subsequent Event [Line Items] Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Income Interest Expense Nonoperating Income (Expense) Shares, Outstanding Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities PrepaidExpensesTextBlock RelatedPartyConvertiblePromissoryNoteTextBlock Schedule of Other Current Assets [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Operating Leases, Future Minimum Payments Due Total [Default Label] EX-101.PRE 8 rcar-20220331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
 3 Months Ended
Mar. 31, 2022
May 10, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-30156  
Entity Registrant Name RENOVACARE, INC.  
Entity Central Index Key 0001016708  
Entity Tax Identification Number 98-0384030  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 9375 E. Shea Blvd.  
Entity Address, Address Line Two Suite 107-A  
Entity Address, City or Town Scottsdale  
Entity Address, State or Province AZ  
Entity Address, Postal Zip Code 85260  
City Area Code 888  
Local Phone Number 398-0202  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   87,352,364
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash $ 1,869,865 $ 2,849,192
Prepaid expenses 905,997 533,445
Total current assets 2,775,862 3,382,637
Equipment, net of accumulated depreciation of $15,275 and $12,952, respectively 26,949 29,271
Intangible assets 152,854 152,854
Security Deposit 7,995 7,995
Right of Use Asset 15,866 28,630
Other Assets 28,997 50,747
Total assets 3,008,523 3,652,134
Current liabilities    
Accounts payable and accrued liabilities 1,369,851 1,274,748
Lease liability - current 17,578 30,497
Total current liabilities 1,387,429 1,305,245
Convertible promissory note to related party 800,000
Interest payable on convertible promissory note to related party 289
Total liabilities 2,187,718 1,305,245
Stockholders' equity    
Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at March 31, 2022 and December 31, 2021 874 874
Additional paid-in capital 36,787,169 36,585,919
Retained deficit (35,967,238) (34,239,904)
Total stockholders' equity 820,805 2,346,889
Total liabilities and stockholders' equity $ 3,008,523 $ 3,652,134
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Accumulated depreciation $ 15,275 $ 12,952
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, Authorized 10,000,000 10,000,000
Preferred stock, shares Issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, Authorized 500,000,000 500,000,000
Common stock, shares Issued 87,352,364 87,352,364
Common stock, shares outstanding 87,352,364 87,352,364
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenue
Operating expenses    
Research and development 596,254 1,054,293
General and administrative 1,146,556 (537,044)
Total operating expenses, net (1,742,810) 517,249
Loss from operations   (517,249)
Other income    
Interest income 950 7
Other income 14,815
Interest expense (289)
Total other income 15,476 7
Net loss $ (1,727,334) $ (517,242)
Basic and Diluted Loss per Common Share $ (0.02) $ (0.01)
Weighted average number of common shares outstanding - basic and diluted 87,352,364 87,352,364
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 874 $ 36,846,082 $ (29,768,181) $ 7,078,775
Beginning balance, shares at Dec. 31, 2020 87,352,364      
Stock based compensation due to common stock purchase options 352,063 352,063
Reversal of stock-based compensation due to common stock purchase option cancellations (1,248,575) (1,248,575)
Net loss (517,242) (517,242)
Ending balance, value at Mar. 31, 2021 $ 874 35,949,570 (30,285,423) 5,665,021
Ending balance, shares at Mar. 31, 2021 87,352,364      
Beginning balance, value at Dec. 31, 2021 $ 874 36,585,919 (34,239,904) 2,346,889
Beginning balance, shares at Dec. 31, 2021 87,352,364      
Stock based compensation due to common stock purchase options 201,250 201,250
Net loss (1,727,334) (1,727,334)
Ending balance, value at Mar. 31, 2022 $ 874 $ 36,787,169 $ (35,967,238) $ 820,805
Ending balance, shares at Mar. 31, 2022 87,352,364      
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows used in operating activities    
Net loss $ (1,727,334) $ (517,242)
Adjustments to reconcile net loss to net cash flows used in operating activities    
Depreciation expense 2,322 2,324
Stock based compensation expense 223,000 (874,760)
Non cash lease expense (155) 1,649
Changes in operating assets and liabilities:    
(Increase) decrease in prepaid expenses and other assets (372,552) 104,104
Increase (decrease) in accounts payable 95,103 (521,199)
Increase (decrease) in related party interest payable 289
Net cash flows used in operating activities (1,779,327) (1,805,124)
Cash flows from financing activities    
Proceeds from the issuance of a related party convertible promissory note 800,000
Net cash flows from financing activities 800,000
Decrease in cash (979,327) (1,805,124)
Cash at beginning of period 2,849,192 7,412,969
Cash at end of period $ 1,869,865 $ 5,607,845
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share

Note 1. Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share

 

Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (“RenovaCare” or the “Company”) as of March 31, 2022, and for the three months ended March 31, 2022 and 2021 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for  quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.

 

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2022, results of operations and stockholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 

Organization

 

RenovaCare, Inc., formerly Janus Resources, is a Nevada corporation. RenovaCare, Inc. was incorporated under the laws of the State of Utah on July 14, 1983 as Far West Gold, Inc.

 

The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of March 31, 2022, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.

 

RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.

 

On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”). The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the “SkinGunTM”) as a cell therapy onto wounds including burns to facilitate healing.

 

Currently, the Company’s proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Liechtenstein, and the United Kingdom. The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.

 

The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

 

Going Concern

 

The Company has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. At March 31, 2022, the Company had approximately $1,870,000 in cash on hand, current liabilities of $1,387,429 and an accumulated deficit of $35,967,238. The Company has historically funded its operations through the issuance of convertible notes, the sale of common stock and issuance of warrants.

 

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans, which are subject to change, management believes that the Company’s existing cash as of March 31, 2022 is insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.

 

The Company is responsible to bear the costs to defend itself and its directors and officers, pursuant to the indemnification clause in the Company’s bylaws, against various Lawsuits (as defined in “Note 7. Commitments and Contingencies—Legal Proceedings” below) currently consisting of a civil action filed by the SEC and two class actions and three derivative actions. See “Note 7. Commitments and Contingencies—Legal Proceedings.” The legal costs to defend the Company against the Lawsuits are expected to be material. During the three months ended March 31, 2022, the Company made legal retainer payments totaling $1,180,000 and incurred $864,000 in legal costs related to the Lawsuits. To assist the Company in paying the costs to defend against the Lawsuits, Kalen Capital Corporation, an Alberta Canada corporation (“Kalen Capital”) which is wholly-owned by the Mr. Harmel S. Rayat (“Mr. Rayat”), the Company’s President, Chief Executive Officer and Chairman, loaned the Company $800,000 on March 18, 2022, as evidenced by the Unsecured Note (as defined in “Note 3. Related Party Convertible Promissory Note” below). Due to the nature and early stage of the Lawsuits, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.

 

The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The future of the Company will depend on its ability to successfully raise capital from external sources. As noted above, management believes that the Company’s existing cash as of March 31, 2022 are insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future product development and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Debt financing may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of the Company’s assets.

 

Accounting Pronouncements

 

The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Consolidated Financial Statements.

 

New Accounting Pronouncements Not Yet Adopted

 

None.

 

Accounting Pronouncements Recently Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40),” to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly changed the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. For smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard on January 1, 2022, with no impact to its financial statements.

 

Earnings (Loss) Per Share

 

The Company presents both basic and diluted earnings per share ("EPS"). Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants or stock options on net loss per share because to do so would be antidilutive.

 

Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2022 and 2021:

 

          
   Three Months Ended
   March 31,
   2022  2021
Basic and Diluted EPS Computation          
Numerator:          
Loss available to common stockholders'  $(1,727,334)  $(517,242)
Denominator:          
Weighted average number of common shares outstanding   87,352,364    87,352,364 
Basic and diluted EPS  $(0.02)  $(0.01)
           
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:          
Stock options   3,099,999    3,164,999 
Warrants   11,705,250    12,296,912 
Total shares not included in the computation of diluted losses per share   14,805,249    15,461,911 

 
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses
 3 Months Ended
Mar. 31, 2022
Prepaid Expenses  
Prepaid Expenses

Note 2. Prepaid Expenses

 

Prepaid expenses and other current assets consist of the following:

 

Schedule of prepaid expenses and other current assets          
   March 31,  December 31,
   2022  2021
Prepaid stock options for services   87,000    87,001 
Prepaid professional fees   626,126    100,930 
Prepaid research and development expense   173,124    289,746 
Other prepaid costs   19,747    13,964 
Refunds due   -    41,804 
Total prepaid expenses  $905,997   $533,445 

 
XML 17 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Convertible Promissory Note
 3 Months Ended
Mar. 31, 2022
Related Party Convertible Promissory Note  
Related Party Convertible Promissory Note

Note 3. Related Party Convertible Promissory Note

 

On March 18, 2022, the Company issued an Unsecured Convertible Promissory Note (the “Unsecured Note”) to Kalen Capital. Pursuant to the terms of the Unsecured Note, Kalen Capital loaned the Company $800,000 at an annual interest rate of 1% per year, compounded daily. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Unsecured Note, and any balance thereunder, automatically converts into securities of the Company upon receipt of an equity financing from third-party(s) of not less than ten million dollars ($10,000,000) at a conversion price equal to 80% of the price paid in such a financing. Also, after June 23, 2023, Kalen Capital may convert all or any portion of the balance into shares of common stock at a conversion price of $0.45 per share, representing a fifty 50% percent premium to the closing price of the Company’s common stock on March 17, 2022. There is no commitment from Kalen Capital for any additional funding.

 

During the three months ended March 31, 2022, the Company recognized $289 of interest expense.

 
XML 18 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Payable and Accrued Liabilities
 3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities

Note 4. Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued expenses consists of the following:

          
  

March 31,

   2022  2021
Legal fees and related  $1,176,033   $869,950 
Officer compensation   -    55,040 
Consultants   5,679    117,943 
Trade payables   188,139    231,815 
Total  $1,369,851   $1,274,748 

 
XML 19 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Equity
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Equity

Note 5. Equity

 

Common Stock

 

At March 31, 2022, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share and 87,352,364 shares of common stock outstanding.

 

Warrants

 

The Company has issued warrants to purchase common stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information about warrants outstanding at March 31, 2022 and December 31, 2020:

 

                  
   Shares of Common Stock Issuable from
Warrants Outstanding as of		  Weighted   
   March 31,  December 31,  Average   
Description  2022  2021  Exercise Price  Expiration
Series F   -    7,246   $3.45   February 23, 2022 & March 9, 2022
Series G   460,250    460,250   $2.68   July 21, 2022
Series H   910,000    910,000   $2.75   October 16, 2022
Series I   10,335,000    10,335,000   $2.00   November 26, 2025
Total   11,705,250    12,296,912         

 

During the three months ended March 31, 2022, all the Series F Warrants expired unexercised.

 

Stock Options

 

The following table summarizes stock option activity for the three months ended March 31, 2022:

 

                    
   Number of
Options		  Weighted
Average
Exercise
Price ($)		  Weighted
Average
Remaining
Contractual
Term
(years)		  Aggregate
Intrinsic
Value ($)
Outstanding at December 31, 2020   5,895,570    2.45           
Granted   50,000    1.72           
Forfeited   (2,805,571)   2.74           
Outstanding at September 30, 2021   3,139,999    2.17           
Forfeited   (40,000)   1.79           
Outstanding at March 31, 2022   3,099,999    2.17    4.30    - 
Vested and exercisable at March 31, 2022   2,699,999    2.02    4.30    - 

 

The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three months ended March 31, 2022 and 2021:

 

          
   Three Months Ended March 31,
   2022  2021
Research and development  $217,500   $278,815 
General and administrative   5,500    (1,153,575)
Total  $223,000   $(874,760)

 
XML 20 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
 3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Leases

Note 6. Leases

 

In February 2020, the Company entered into a two-year lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey (the “Premises”). Monthly base rent in year one of the lease is $4,356; and $4,459 in year 2 of the lease. The term (and payment of the monthly rent) commenced upon completion of the landlord’s work on August 1, 2020. The Company vacated the premises in May of 2021 and relocated its corporate offices to 9375 E. Shea Blvd., Suite 107-A, Scottsdale, AZ 85260.

 

The Company’s existing lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s.

 

As of March 31, 2022, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations.

 

The Company does not have any finance leases.

 

 Supplemental lease information:

 

      
   As of March 31,  As of December 31,
   2022  2021
Operating lease right-of-use asset  $15,866   $28,630 
           
Current maturities of operating lease  $17,578   $30,497 
Current maturities of operating lease in accounts payable   8,918    - 
Total operating lease liabilities  $26,496   $30,497 
           
           
Weighted Average remaining lease term (in years):   0.34    0.58 
Right-of-use asset obtained in exchange for lease obligation   -   $

98,405

 

 

Supplemental information for the three months ended March 31, 2022 and 2021:

 

   2022  2021
Cash paid for amount included in the measurement of lease liabilities for operating lease  $4,459   $13,068 

 

The Company leases office space under a non-cancellable operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at March 31, 2022 for future periods are as follows:

 

     
2022   26,754 
Total future minimum lease payments   26,754 
Less imputed interest   (538)
Total  $26,216 

 
XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 7. Commitments and Contingencies

 

Stem Cell Systems

 

In connection with the Company’s anticipated future regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with medical device prototypes and related design documents and data under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&D Agreement (the “Strategic Agreement”) having an initial term of three years with successive one-year extensions unless earlier terminated. The Strategic Agreement includes a $39,000 monthly fee to be paid to StemCell Systems along with any additional expenses incurred. The Company, StemCell Systems and certain affiliates of StemCell Systems entered into a Rights of First Refusal and Corporate Opportunities Agreement (the “ROFR Agreement”). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Company’s acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of $125,931 and $120,377 during the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the Company had a balance due to StemCell Systems of $83,700. On April 28, 2022 the Company provided StemCell Systems with notice of termination of the Strategic Agreement. See “Note 8. Subsequent Events.”

Legal Proceedings

 

SEC Civil Complaint

 

On May 28, 2021 the SEC filed a civil complaint (the “SEC Action”), in the United States District Court for the Southern District of New York, naming the Company and Harmel S. Rayat, the Company’s current President, Chief Executive Officer, Chief Financial Officer and Sole Director as defendants (the “Defendants”). The SEC Action alleges among other things that Mr. Rayat and the Company with violated the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also alleges that Mr. Rayat aided and abetted the violations of those provisions by the Company. The SEC Action also alleges that the Company violated the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks, among other relief, permanent injunctions and civil penalties against the Defendants, and officer-and-director and penny stock bars against Mr. Rayat. On August 31, 2021 the Defendants filed an answer to the Complaint. On September 21, 2021, the SEC filed a motion to strike Defendants equitable affirmative defenses which motion was granted by the court on October 18, 2021. The Company continues to defend itself and the named individuals against the allegations set forth in the SEC Action. Due to the nature and early stage of the SEC Action, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.

 

Class Action Complaints

 

On July 16, 2021, Gabrielle A. Boller filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the “Boller Lawsuit”), against the Company and certain past and current officers and members of the Company’s board of directors (collectively, the “Boller Defendants”). The Boller Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the SEC Action, the Boller Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Boller Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred in the Boller Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.

 

The Company disputes the plaintiffs’ claims in the Boller Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Boller Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

On July 21, 2021, Michael Solakian, filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the “Solakian Lawsuit”), against the Company and certain past and current officers and members of the Company’s board of directors (collectively, the “Solakian Defendants”). The Solakian Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the SEC Action, the Solakian Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Solakian Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred in the Solakian Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.

 

The Company disputes the plaintiffs’ claims in the Solakian Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Solakian Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

Shareholder Derivative Complaints

 

On December 20, 2021, Melvin Emberland (“Emberland”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “Emberland Lawsuit”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “Emberland Defendants”). In the complaint, Emberland’s allegations, relating to the facts and circumstances underlying the allegations in the SEC Action include, but are not limited to (i) breach of fiduciary duties by the individual Emberland Defendants, (ii) unjust enrichment and (iii) violation of Section 10(b) and 21D of the Securities Exchange Act of 1934. Emberland did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Emberland seeks (i) a declaration that the Emberland Defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company, (ii) a determination awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Emberland Defendants, (iii) a directive to the Company and the Emberland Defendants to take all necessary actions to reform and improve the Company’s corporate governance and internal procedures to comply with applicable laws, and (iv) Plaintiff is seeking, among other things, restitution from the individual Emberland Defendants and disgorgement of profits, benefits and other compensation obtained by such Emberland Defendants, costs and disbursements of the action including reasonable attorney’s fees, accountants’ and expert fees and expenses, an order directing the taking of certain corporate actions relating to its board of directors and corporate governance.

 

The Company disputes Emberland’s claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Emberland Defendants. Given the uncertainty of litigation, the preliminary stage of the Emberland Lawsuit, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

On January 6, 2022, Zoser Vargas (“Vargas”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “Vargas Lawsuit”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “Vargas Defendants”). In the complaint Vargas’ allegations relating to the facts and circumstances underlying the allegations in the SEC Action include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the Vargas Defendants’ breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Vargas Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Vargas Defendants.

 

The Company disputes Vargas’ claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Vargas Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

On January 28, 2022, Aviva Meyer (“Meyer”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “Meyer Lawsuit”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “Meyer Defendants”). In the complaint Meyer’s allegations relating to the facts and circumstances underlying the allegations in the SEC Action include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the Vargas Defendants’ breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Meyer Defendants.

 

The Company disputes Meyer’s claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Meyer Defendants Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

 

The Company believes that the claims asserted in the SEC Action, the Boller Lawsuit, the Solakian Lawsuit, the Emberland Lawsuit, the Vargas Lawsuit, and the Meyer Lawsuit (collectively, the “Lawsuits”) are without merit and intends to vigorously defend each Lawsuit.

 
XML 22 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 8. Subsequent Events

 

Management has reviewed material events subsequent of the period ended March 31, 2022 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

 

On April 21, 2022, the Company made retainer payments to its attorneys in the amount of $1,180,000.

 

On April 28, 2022, the Company terminated the Strategic Agreement with StemCell Systems.
XML 23 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (“RenovaCare” or the “Company”) as of March 31, 2022, and for the three months ended March 31, 2022 and 2021 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for  quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.

 

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2022, results of operations and stockholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 
Organization

Organization

 

RenovaCare, Inc., formerly Janus Resources, is a Nevada corporation. RenovaCare, Inc. was incorporated under the laws of the State of Utah on July 14, 1983 as Far West Gold, Inc.

 

The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of March 31, 2022, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.

 

RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.

 

On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”). The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the “SkinGunTM”) as a cell therapy onto wounds including burns to facilitate healing.

 

Currently, the Company’s proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Liechtenstein, and the United Kingdom. The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.

 

The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

 
Going Concern

Going Concern

 

The Company has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. At March 31, 2022, the Company had approximately $1,870,000 in cash on hand, current liabilities of $1,387,429 and an accumulated deficit of $35,967,238. The Company has historically funded its operations through the issuance of convertible notes, the sale of common stock and issuance of warrants.

 

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans, which are subject to change, management believes that the Company’s existing cash as of March 31, 2022 is insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.

 

The Company is responsible to bear the costs to defend itself and its directors and officers, pursuant to the indemnification clause in the Company’s bylaws, against various Lawsuits (as defined in “Note 7. Commitments and Contingencies—Legal Proceedings” below) currently consisting of a civil action filed by the SEC and two class actions and three derivative actions. See “Note 7. Commitments and Contingencies—Legal Proceedings.” The legal costs to defend the Company against the Lawsuits are expected to be material. During the three months ended March 31, 2022, the Company made legal retainer payments totaling $1,180,000 and incurred $864,000 in legal costs related to the Lawsuits. To assist the Company in paying the costs to defend against the Lawsuits, Kalen Capital Corporation, an Alberta Canada corporation (“Kalen Capital”) which is wholly-owned by the Mr. Harmel S. Rayat (“Mr. Rayat”), the Company’s President, Chief Executive Officer and Chairman, loaned the Company $800,000 on March 18, 2022, as evidenced by the Unsecured Note (as defined in “Note 3. Related Party Convertible Promissory Note” below). Due to the nature and early stage of the Lawsuits, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.

 

The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The future of the Company will depend on its ability to successfully raise capital from external sources. As noted above, management believes that the Company’s existing cash as of March 31, 2022 are insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future product development and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Debt financing may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of the Company’s assets.

 
Accounting Pronouncements

Accounting Pronouncements

 

The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Consolidated Financial Statements.

 

New Accounting Pronouncements Not Yet Adopted

 

None.

 

Accounting Pronouncements Recently Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40),” to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly changed the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. For smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard on January 1, 2022, with no impact to its financial statements.

 
Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

The Company presents both basic and diluted earnings per share ("EPS"). Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants or stock options on net loss per share because to do so would be antidilutive.

 

Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2022 and 2021:

 

          
   Three Months Ended
   March 31,
   2022  2021
Basic and Diluted EPS Computation          
Numerator:          
Loss available to common stockholders'  $(1,727,334)  $(517,242)
Denominator:          
Weighted average number of common shares outstanding   87,352,364    87,352,364 
Basic and diluted EPS  $(0.02)  $(0.01)
           
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:          
Stock options   3,099,999    3,164,999 
Warrants   11,705,250    12,296,912 
Total shares not included in the computation of diluted losses per share   14,805,249    15,461,911 

 
XML 24 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Tables)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Schedule of computation of basic and diluted net loss per share
          
   Three Months Ended
   March 31,
   2022  2021
Basic and Diluted EPS Computation          
Numerator:          
Loss available to common stockholders'  $(1,727,334)  $(517,242)
Denominator:          
Weighted average number of common shares outstanding   87,352,364    87,352,364 
Basic and diluted EPS  $(0.02)  $(0.01)
           
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:          
Stock options   3,099,999    3,164,999 
Warrants   11,705,250    12,296,912 
Total shares not included in the computation of diluted losses per share   14,805,249    15,461,911 
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses (Tables)
 3 Months Ended
Mar. 31, 2022
Prepaid Expenses  
Prepaid Expenses
Schedule of prepaid expenses and other current assets          
   March 31,  December 31,
   2022  2021
Prepaid stock options for services   87,000    87,001 
Prepaid professional fees   626,126    100,930 
Prepaid research and development expense   173,124    289,746 
Other prepaid costs   19,747    13,964 
Refunds due   -    41,804 
Total prepaid expenses  $905,997   $533,445 
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Payable and Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
Schedule of accounts payable and accrued expenses
          
  

March 31,

   2022  2021
Legal fees and related  $1,176,033   $869,950 
Officer compensation   -    55,040 
Consultants   5,679    117,943 
Trade payables   188,139    231,815 
Total  $1,369,851   $1,274,748 
XML 27 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Tables)
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of warrants outstanding
                  
   Shares of Common Stock Issuable from
Warrants Outstanding as of		  Weighted   
   March 31,  December 31,  Average   
Description  2022  2021  Exercise Price  Expiration
Series F   -    7,246   $3.45   February 23, 2022 & March 9, 2022
Series G   460,250    460,250   $2.68   July 21, 2022
Series H   910,000    910,000   $2.75   October 16, 2022
Series I   10,335,000    10,335,000   $2.00   November 26, 2025
Total   11,705,250    12,296,912         
Schedule of stock option activity
                    
   Number of
Options		  Weighted
Average
Exercise
Price ($)		  Weighted
Average
Remaining
Contractual
Term
(years)		  Aggregate
Intrinsic
Value ($)
Outstanding at December 31, 2020   5,895,570    2.45           
Granted   50,000    1.72           
Forfeited   (2,805,571)   2.74           
Outstanding at September 30, 2021   3,139,999    2.17           
Forfeited   (40,000)   1.79           
Outstanding at March 31, 2022   3,099,999    2.17    4.30    - 
Vested and exercisable at March 31, 2022   2,699,999    2.02    4.30    - 
Condensed Income Statement [Table Text Block]
          
   Three Months Ended March 31,
   2022  2021
Research and development  $217,500   $278,815 
General and administrative   5,500    (1,153,575)
Total  $223,000   $(874,760)

 
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Schedule of supplemental lease information
      
   As of March 31,  As of December 31,
   2022  2021
Operating lease right-of-use asset  $15,866   $28,630 
           
Current maturities of operating lease  $17,578   $30,497 
Current maturities of operating lease in accounts payable   8,918    - 
Total operating lease liabilities  $26,496   $30,497 
           
           
Weighted Average remaining lease term (in years):   0.34    0.58 
Right-of-use asset obtained in exchange for lease obligation   -   $

98,405

 

 

Supplemental information for the three months ended March 31, 2022 and 2021:

 

   2022  2021
Cash paid for amount included in the measurement of lease liabilities for operating lease  $4,459   $13,068 
Schedule of future lease payments
     
2022   26,754 
Total future minimum lease payments   26,754 
Less imputed interest   (538)
Total  $26,216 
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator:    
Loss available to common stockholders' $ (1,727,334) $ (517,242)
Denominator:    
Weighted average number of common shares outstanding 87,352,364 87,352,364
Basic and diluted EPS $ (0.02) $ (0.01)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:    
Total shares not included in the computation of diluted losses per share 14,805,249 15,461,911
Share-Based Payment Arrangement [Member]    
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:    
Total shares not included in the computation of diluted losses per share 3,099,999 3,164,999
Warrant [Member]    
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:    
Total shares not included in the computation of diluted losses per share 11,705,250 12,296,912
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 18, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Entity Incorporation, State or Country Code NV    
Date of Incorporation Jul. 14, 1983    
Common stock, Authorized 500,000,000   500,000,000
Common stock, par value $ 0.00001   $ 0.00001
Common stock, shares Issued 87,352,364   87,352,364
Common stock, shares outstanding 87,352,364   87,352,364
Preferred stock, Authorized 10,000,000   10,000,000
Preferred stock, par value $ 0.0001   $ 0.0001
Preferred stock, shares Issued 0   0
Preferred stock, shares outstanding 0   0
Cash on hand $ 1,870,000    
Current liability 1,387,429   $ 1,305,245
Accumulated deficit 35,967,238   $ 34,239,904
Kalen Capital [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Legal Fees 864,000    
Loan   $ 800,000  
Attorneys [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payments to retainer $ 1,180,000    
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Prepaid Expenses    
Prepaid stock options for services $ 87,000 $ 87,001
Prepaid professional fees 626,126 100,930
Prepaid research and development expense 173,124 289,746
Other prepaid costs 19,747 13,964
Refunds due 41,804
Total prepaid expenses $ 905,997 $ 533,445
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Convertible Promissory Note (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Mar. 18, 2022
Mar. 31, 2022
Defined Benefit Plan Disclosure [Line Items]    
Interest expense   $ 289
Kalen Capital Corp [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Loan $ 800,000  
Interest rate 1.00%  
Conversion price $ 0.45  
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Payable and Accrued Liabilities (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Legal fees and related $ 1,176,033 $ 869,950
Officer compensation 55,040
Consultants 5,679 117,943
Trade payables 188,139 231,815
Total $ 1,369,851 $ 1,274,748
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Details) - $ / shares
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Series F [Member]    
Class of Warrant or Right [Line Items]    
Shares of Common Stock Issuable from Warrants Outstanding 7,246
Weighted Average Exercise Price $ 3.45 $ 3.45
Series F [Member] | Minimum [Member]    
Class of Warrant or Right [Line Items]    
Expiration Feb. 23, 2022  
Series F [Member] | Maximum [Member]    
Class of Warrant or Right [Line Items]    
Expiration Mar. 09, 2022  
Series G [Member]    
Class of Warrant or Right [Line Items]    
Shares of Common Stock Issuable from Warrants Outstanding 460,250 460,250
Weighted Average Exercise Price $ 2.68 $ 2.68
Expiration Jul. 21, 2022  
Series H [Member]    
Class of Warrant or Right [Line Items]    
Shares of Common Stock Issuable from Warrants Outstanding 910,000 910,000
Weighted Average Exercise Price $ 2.75 $ 2.75
Expiration Oct. 16, 2022  
Series I [Member]    
Class of Warrant or Right [Line Items]    
Shares of Common Stock Issuable from Warrants Outstanding 10,335,000 10,335,000
Weighted Average Exercise Price $ 2.00 $ 2.00
Expiration Nov. 26, 2025  
Warrant [Member]    
Class of Warrant or Right [Line Items]    
Shares of Common Stock Issuable from Warrants Outstanding 11,705,250 12,296,912
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Details 1) - USD ($)
 6 Months Ended 9 Months Ended
Mar. 31, 2022
Sep. 30, 2021
Equity [Abstract]    
Options outstanding - beginning balance 3,139,999 5,895,570
Options outstanding - beginning balance $ 2.17 $ 2.45
Options granted   50,000
Options granted   $ 1.72
Options forfeited (40,000) (2,805,571)
Options forfeited $ 1.79 $ 2.74
Options oustanding - ending balance 3,099,999 3,139,999
Options outstanding - ending balance $ 2.17 $ 2.17
Weighted average remaining contracted term 4 years 3 months 18 days  
Aggregate intrinsic value  
Options Vested and Exercisable 2,699,999  
Options Vested and Exercisable $ 2.02  
Options Vested and Exercisable 4 years 3 months 18 days  
Options Vested and Exercisable  
XML 36 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Details 2) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Total $ 223,000 $ (874,760)
Research and Development Expense [Member] | Share-Based Payment Arrangement, Option [Member]    
Total 217,500 278,815
General and Administrative Expense [Member] | Share-Based Payment Arrangement, Option [Member]    
Total $ 5,500 $ (1,153,575)
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Details Narrative) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Common stock, Authorized 500,000,000 500,000,000
Common stock, par value $ 0.00001 $ 0.00001
Common stock, shares Issued 87,352,364 87,352,364
Common stock, shares outstanding 87,352,364 87,352,364
XML 38 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Leases [Abstract]      
Operating lease right-of-use asset $ 15,866   $ 28,630
Current maturities of operating lease 17,578   30,497
Current maturities of operating lease in accounts payable 8,918  
Total operating lease liabilities $ 26,496   $ 30,497
Weighted Average remaining lease term (in years): 4 months 2 days   6 months 29 days
Right-of-use asset obtained in exchange for lease obligation $ 98,405  
Cash paid for amount included in the measurement of lease liabilities for operating lease $ 4,459 $ 13,068  
XML 39 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details 1)
Mar. 31, 2022
USD ($)
Leases [Abstract]  
2022 $ 26,754
Total future minimum lease payments 26,754
Less imputed interest (538)
Total $ 26,216
XML 40 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Details Narrative)
 3 Months Ended
Mar. 31, 2022
USD ($)
Leases [Abstract]  
Base rent for First year $ 4,356
Base rent for Second year $ 4,459
Lease term 2 years
XML 41 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details Narrative) - StemCell Systems [Member] - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]    
Periodic Payment $ 39,000  
Incurred expenses 125,931 $ 120,377
Due to related party $ 83,700  
XML 42 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details Narrative) - Attorneys [Member] - USD ($)
 1 Months Ended 3 Months Ended
Apr. 21, 2022
Mar. 31, 2022
Subsequent Event [Line Items]    
Payments to retainer   $ 1,180,000
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Payments to retainer $ 1,180,000  
XML 43 f10q_051022p_htm.xml IDEA: XBRL DOCUMENT 0001016708 2022-01-01 2022-03-31 0001016708 2022-05-10 0001016708 2022-03-31 0001016708 2021-12-31 0001016708 2021-01-01 2021-03-31 0001016708 us-gaap:CommonStockMember 2021-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001016708 us-gaap:RetainedEarningsMember 2021-12-31 0001016708 us-gaap:CommonStockMember 2020-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001016708 us-gaap:RetainedEarningsMember 2020-12-31 0001016708 2020-12-31 0001016708 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001016708 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001016708 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001016708 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001016708 us-gaap:CommonStockMember 2022-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001016708 us-gaap:RetainedEarningsMember 2022-03-31 0001016708 us-gaap:CommonStockMember 2021-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001016708 us-gaap:RetainedEarningsMember 2021-03-31 0001016708 2021-03-31 0001016708 rcar:AttorneysMember 2022-01-01 2022-03-31 0001016708 rcar:KalenCapitalMember 2022-01-01 2022-03-31 0001016708 rcar:KalenCapitalMember 2022-03-18 0001016708 us-gaap:StockCompensationPlanMember 2022-01-01 2022-03-31 0001016708 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001016708 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001016708 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001016708 rcar:KalenCapitalCorpMember 2022-03-18 0001016708 rcar:KalenCapitalCorpMember 2022-03-01 2022-03-18 0001016708 rcar:SeriesFMember 2022-03-31 0001016708 rcar:SeriesFMember 2021-12-31 0001016708 srt:MinimumMember rcar:SeriesFMember 2022-01-01 2022-03-31 0001016708 srt:MaximumMember rcar:SeriesFMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesGMember 2022-03-31 0001016708 rcar:SeriesGMember 2021-12-31 0001016708 rcar:SeriesGMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesHMember 2022-03-31 0001016708 rcar:SeriesHMember 2021-12-31 0001016708 rcar:SeriesHMember 2022-01-01 2022-03-31 0001016708 rcar:SeriesIMember 2022-03-31 0001016708 rcar:SeriesIMember 2021-12-31 0001016708 rcar:SeriesIMember 2022-01-01 2022-03-31 0001016708 us-gaap:WarrantMember 2022-03-31 0001016708 us-gaap:WarrantMember 2021-12-31 0001016708 2021-01-01 2021-09-30 0001016708 2021-09-30 0001016708 2021-10-01 2022-03-31 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001016708 rcar:StemCellSystemsMember 2022-01-01 2022-03-31 0001016708 rcar:StemCellSystemsMember 2021-01-01 2021-03-31 0001016708 rcar:StemCellSystemsMember 2022-03-31 0001016708 rcar:AttorneysMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-21 iso4217:USD shares iso4217:USD shares pure 0001016708 false --12-31 2022 Q1 10-Q true 2022-03-31 false 000-30156 RENOVACARE, INC. NV 98-0384030 9375 E. Shea Blvd. Suite 107-A Scottsdale AZ 85260 888 398-0202 Yes Yes Non-accelerated Filer true false false 87352364 1869865 2849192 905997 533445 2775862 3382637 15275 12952 26949 29271 152854 152854 7995 7995 15866 28630 28997 50747 3008523 3652134 1369851 1274748 17578 30497 1387429 1305245 800000 289 2187718 1305245 0.0001 0.0001 10000000 10000000 0 0 0 0 0.00001 0.00001 500000000 500000000 87352364 87352364 87352364 87352364 874 874 36787169 36585919 -35967238 -34239904 820805 2346889 3008523 3652134 596254 1054293 1146556 -537044 -1742810 517249 -517249 950 7 14815 289 15476 7 -1727334 -517242 -0.02 -0.01 87352364 87352364 87352364 874 36585919 -34239904 2346889 201250 201250 -1727334 -1727334 87352364 874 36787169 -35967238 820805 87352364 874 36846082 -29768181 7078775 352063 352063 -1248575 -1248575 -517242 -517242 87352364 874 35949570 -30285423 5665021 -1727334 -517242 2322 2324 223000 -874760 -155 1649 372552 -104104 95103 -521199 289 -1779327 -1805124 800000 800000 -979327 -1805124 2849192 7412969 1869865 5607845 <p id="xdx_80F_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_z0XHHmjbLca8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1. <span id="xdx_821_zkxduC9TG945">Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zFlmBrqouFT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zjvuqw9gOA2j">Basis of Presentation </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (“RenovaCare” or the “<b>Company</b>”) as of March 31, 2022, and for the three months ended March 31, 2022 and 2021 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“<b>SEC</b>”) for  quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“<b>U.S. GAAP</b>”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2022, results of operations and stockholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_847_ecustom--OrganizationPolicyTextBlock_z27iGmsXRX3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zkD3Ryq5SyLa">Organization</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RenovaCare, Inc., formerly Janus Resources, is a <span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220101__20220331">Nevada</span> corporation. RenovaCare, Inc. was incorporated under the laws of the State of Utah on <span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_c20220101__20220331" title="Date of Incorporation">July 14, 1983</span> as Far West Gold, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an authorized capital of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_zAR8qc8Idmp3" title="Common stock, Authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zZwGGGd6lqxj" title="Common stock, Authorized">500,000,000</span></span> shares of $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_zvqiXQ6XsIt2" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zTmwd5JILrKf" title="Common stock, par value">0.00001</span></span> par value common stock, of which <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20220331_z1We4Ewd2XGc" title="Common stock, shares Issued"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20211231_zOxyEKTqkCdj" title="Common stock, shares Issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zH983gkOQFi8" title="Common stock, shares outstanding"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zQIUiEUVCtEj" title="Common stock, shares outstanding">87,352,364</span></span></span></span> shares are outstanding as of March 31, 2022, and <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331_zYAaZxy936md" title="Preferred stock, Authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zS4JI3xRfmn5" title="Preferred stock, Authorized">10,000,000</span></span> shares of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331_zROhxwXKfzBb" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zFf70z1EX1Vg" title="Preferred stock, par value">0.0001</span></span> par value preferred stock, of which <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220331_zAT5OlGr2mSg" title="Preferred stock, shares Issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zfGPjI2upwDk" title="Preferred stock, shares Issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220331_zWrmBaJY3Eqd" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_z6tVqC0d8Ie2" title="Preferred stock, shares outstanding">none</span></span></span></span> are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “<b>CellMist<sup>TM </sup>System</b>”). <span style="color: #212121">The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from </span>the Company’s novel solution sprayer device (the “<b>SkinGun<sup>TM</sup></b>”) <span style="color: #212121">as a cell therapy onto wounds including burns to facilitate healing. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212121"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify"><span style="background-color: white">Currently, the Company’s proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Liechtenstein, and the United Kingdom.</span> The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_84A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUPVC2bEBnF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i/></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zro3v35BTbyb">Going Concern</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. <span style="background-color: white">At March 31, 2022, the Company had approximately $<span id="xdx_90B_eus-gaap--Cash_c20220331_pp0p0" title="Cash on hand">1,870,000</span> in cash on hand, current liabilities of $<span id="xdx_900_eus-gaap--LiabilitiesCurrent_c20220331_pp0p0" title="Current liability">1,387,429</span> and an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220331_zIgSUN1nXtE" title="Accumulated deficit">35,967,238</span>. </span>The Company has historically funded its operations through the issuance of convertible notes, the sale of common stock and issuance of warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans, which are subject to change, management believes that the Company’s existing cash as of March 31, 2022 is insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is responsible to bear the costs to defend itself and its directors and officers, pursuant to the indemnification clause in the Company’s bylaws, against various Lawsuits (as defined in “Note 7. Commitments and Contingencies—Legal Proceedings” below) currently consisting of a civil action filed by the SEC and two class actions and three derivative actions. See “Note 7. Commitments and Contingencies—Legal Proceedings.” The legal costs to defend the Company against the Lawsuits are expected to be material. During the three months ended March 31, 2022, the Company made legal retainer payments totaling $<span id="xdx_907_ecustom--PaymentsToRetainer_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--AttorneysMember_zBMwPyT9qYoa" title="Payments to retainer">1,180,000</span> and incurred $<span id="xdx_90C_eus-gaap--LegalFees_pp0p0_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalMember_zHmvy0ZGAwod" title="Legal Fees">864,000</span> in legal costs related to the Lawsuits. To assist the Company in paying the costs to defend against the Lawsuits, Kalen Capital Corporation, an Alberta Canada corporation (“<b>Kalen Capital</b>”) which is wholly-owned by the Mr. Harmel S. Rayat (“<b>Mr. Rayat</b>”), the Company’s President, Chief Executive Officer and Chairman, loaned the Company $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220318__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalMember_zuBIRdQ5edFe" title="Loan">800,000</span> on March 18, 2022, as evidenced by the Unsecured Note (as defined in “Note 3. Related Party Convertible Promissory Note” below). Due to the nature and early stage of the Lawsuits, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The future of the Company will depend on its ability to successfully raise capital from external sources. As noted above, management believes that the Company’s existing cash as of March 31, 2022 are insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future product development and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Debt financing may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of the Company’s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZkmmdRcouj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zqY1cUUSpKO3">Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Consolidated Financial Statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>New Accounting Pronouncements Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">None.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Accounting Pronouncements Recently Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40),” to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly changed the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. For smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard on January 1, 2022, with no impact to its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zHtuWsbDacD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Earnings (Loss) Per Share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company presents both basic and diluted earnings per share ("<b>EPS</b>"). Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants or stock options on net loss per share because to do so would be antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4Qtp05ED9e9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B8_zvWBZ4DZZsti" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20220101__20220331_zyznquOGdsoa" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210101__20210331_zGi42Qi2liPd" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_405_ecustom--BasicAndDilutedEpsComputationAbstract_iB_zpk8K0fkTFGf" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: left; padding-left: 10pt">Loss available to common stockholders'</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,727,334</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(517,242</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,352,364</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,352,364</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BasicAndDilutedEps_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Basic and diluted EPS</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(0.02</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(0.01</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_z73sNMhTrlwl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left; padding-left: 10pt">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="text-align: right" title="Total shares not included in the computation of diluted losses per share">3,099,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="text-align: right" title="Total shares not included in the computation of diluted losses per share">3,164,999</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares not included in the computation of diluted losses per share">11,705,250</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total shares not included in the computation of diluted losses per share</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Total shares not included in the computation of diluted losses per share">14,805,249</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,461,911</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b/></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zFlmBrqouFT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zjvuqw9gOA2j">Basis of Presentation </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (“RenovaCare” or the “<b>Company</b>”) as of March 31, 2022, and for the three months ended March 31, 2022 and 2021 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“<b>SEC</b>”) for  quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“<b>U.S. GAAP</b>”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on March 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2022, results of operations and stockholders’ equity for the three months ended March 31, 2022 and 2021, and cash flows for the three months ended March 31, 2022 and 2021. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_847_ecustom--OrganizationPolicyTextBlock_z27iGmsXRX3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zkD3Ryq5SyLa">Organization</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RenovaCare, Inc., formerly Janus Resources, is a <span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220101__20220331">Nevada</span> corporation. RenovaCare, Inc. was incorporated under the laws of the State of Utah on <span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_c20220101__20220331" title="Date of Incorporation">July 14, 1983</span> as Far West Gold, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an authorized capital of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_zAR8qc8Idmp3" title="Common stock, Authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zZwGGGd6lqxj" title="Common stock, Authorized">500,000,000</span></span> shares of $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_zvqiXQ6XsIt2" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zTmwd5JILrKf" title="Common stock, par value">0.00001</span></span> par value common stock, of which <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20220331_z1We4Ewd2XGc" title="Common stock, shares Issued"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20211231_zOxyEKTqkCdj" title="Common stock, shares Issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zH983gkOQFi8" title="Common stock, shares outstanding"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zQIUiEUVCtEj" title="Common stock, shares outstanding">87,352,364</span></span></span></span> shares are outstanding as of March 31, 2022, and <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331_zYAaZxy936md" title="Preferred stock, Authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zS4JI3xRfmn5" title="Preferred stock, Authorized">10,000,000</span></span> shares of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331_zROhxwXKfzBb" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zFf70z1EX1Vg" title="Preferred stock, par value">0.0001</span></span> par value preferred stock, of which <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220331_zAT5OlGr2mSg" title="Preferred stock, shares Issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zfGPjI2upwDk" title="Preferred stock, shares Issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220331_zWrmBaJY3Eqd" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_z6tVqC0d8Ie2" title="Preferred stock, shares outstanding">none</span></span></span></span> are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “<b>CellMist<sup>TM </sup>System</b>”). <span style="color: #212121">The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from </span>the Company’s novel solution sprayer device (the “<b>SkinGun<sup>TM</sup></b>”) <span style="color: #212121">as a cell therapy onto wounds including burns to facilitate healing. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212121"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt; text-align: justify"><span style="background-color: white">Currently, the Company’s proprietary technologies are the subject of forty-four (44) U.S. and foreign granted or pending patents or patent applications and seventeen (17) U.S. and foreign trademarks. Of the issued patents, five (5) are U.S. patents and seventeen (17) have issued or are allowed in Australia, Canada, China, Europe, Germany, France, Italy, Japan, Korea, Netherlands, Spain, Switzerland/Liechtenstein, and the United Kingdom.</span> The Company has six (6) allowed trademarks in the United States, two (2) European registered trademarks, two (2) United Kingdom trademarks, two (2) Japan trademarks, and two (2) pending in Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> NV 1983-07-14 500000000 500000000 0.00001 0.00001 87352364 87352364 87352364 87352364 10000000 10000000 0.0001 0.0001 0 0 0 0 <p id="xdx_84A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUPVC2bEBnF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i/></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zro3v35BTbyb">Going Concern</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. <span style="background-color: white">At March 31, 2022, the Company had approximately $<span id="xdx_90B_eus-gaap--Cash_c20220331_pp0p0" title="Cash on hand">1,870,000</span> in cash on hand, current liabilities of $<span id="xdx_900_eus-gaap--LiabilitiesCurrent_c20220331_pp0p0" title="Current liability">1,387,429</span> and an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220331_zIgSUN1nXtE" title="Accumulated deficit">35,967,238</span>. </span>The Company has historically funded its operations through the issuance of convertible notes, the sale of common stock and issuance of warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans, which are subject to change, management believes that the Company’s existing cash as of March 31, 2022 is insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is responsible to bear the costs to defend itself and its directors and officers, pursuant to the indemnification clause in the Company’s bylaws, against various Lawsuits (as defined in “Note 7. Commitments and Contingencies—Legal Proceedings” below) currently consisting of a civil action filed by the SEC and two class actions and three derivative actions. See “Note 7. Commitments and Contingencies—Legal Proceedings.” The legal costs to defend the Company against the Lawsuits are expected to be material. During the three months ended March 31, 2022, the Company made legal retainer payments totaling $<span id="xdx_907_ecustom--PaymentsToRetainer_pp0p0_c20220101__20220331__srt--CounterpartyNameAxis__custom--AttorneysMember_zBMwPyT9qYoa" title="Payments to retainer">1,180,000</span> and incurred $<span id="xdx_90C_eus-gaap--LegalFees_pp0p0_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalMember_zHmvy0ZGAwod" title="Legal Fees">864,000</span> in legal costs related to the Lawsuits. To assist the Company in paying the costs to defend against the Lawsuits, Kalen Capital Corporation, an Alberta Canada corporation (“<b>Kalen Capital</b>”) which is wholly-owned by the Mr. Harmel S. Rayat (“<b>Mr. Rayat</b>”), the Company’s President, Chief Executive Officer and Chairman, loaned the Company $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220318__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalMember_zuBIRdQ5edFe" title="Loan">800,000</span> on March 18, 2022, as evidenced by the Unsecured Note (as defined in “Note 3. Related Party Convertible Promissory Note” below). Due to the nature and early stage of the Lawsuits, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The future of the Company will depend on its ability to successfully raise capital from external sources. As noted above, management believes that the Company’s existing cash as of March 31, 2022 are insufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future product development and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Debt financing may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of the Company’s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> 1870000 1387429 -35967238 1180000 864000 800000 <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZkmmdRcouj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zqY1cUUSpKO3">Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Consolidated Financial Statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>New Accounting Pronouncements Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">None.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Accounting Pronouncements Recently Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40),” to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly changed the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. For smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard on January 1, 2022, with no impact to its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zHtuWsbDacD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Earnings (Loss) Per Share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company presents both basic and diluted earnings per share ("<b>EPS</b>"). Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants or stock options on net loss per share because to do so would be antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4Qtp05ED9e9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B8_zvWBZ4DZZsti" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20220101__20220331_zyznquOGdsoa" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210101__20210331_zGi42Qi2liPd" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_405_ecustom--BasicAndDilutedEpsComputationAbstract_iB_zpk8K0fkTFGf" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: left; padding-left: 10pt">Loss available to common stockholders'</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,727,334</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(517,242</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,352,364</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,352,364</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BasicAndDilutedEps_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Basic and diluted EPS</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(0.02</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(0.01</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_z73sNMhTrlwl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left; padding-left: 10pt">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="text-align: right" title="Total shares not included in the computation of diluted losses per share">3,099,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="text-align: right" title="Total shares not included in the computation of diluted losses per share">3,164,999</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares not included in the computation of diluted losses per share">11,705,250</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total shares not included in the computation of diluted losses per share</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Total shares not included in the computation of diluted losses per share">14,805,249</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,461,911</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b/></p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4Qtp05ED9e9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B8_zvWBZ4DZZsti" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20220101__20220331_zyznquOGdsoa" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210101__20210331_zGi42Qi2liPd" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_405_ecustom--BasicAndDilutedEpsComputationAbstract_iB_zpk8K0fkTFGf" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: left; padding-left: 10pt">Loss available to common stockholders'</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,727,334</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(517,242</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,352,364</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,352,364</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BasicAndDilutedEps_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Basic and diluted EPS</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(0.02</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(0.01</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB_z73sNMhTrlwl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left; padding-left: 10pt">Stock options</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="text-align: right" title="Total shares not included in the computation of diluted losses per share">3,099,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="text-align: right" title="Total shares not included in the computation of diluted losses per share">3,164,999</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares not included in the computation of diluted losses per share">11,705,250</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total shares not included in the computation of diluted losses per share</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Total shares not included in the computation of diluted losses per share">14,805,249</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,461,911</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> -1727334 -517242 87352364 87352364 -0.02 -0.01 3099999 3164999 11705250 12296912 14805249 15461911 <p id="xdx_80A_ecustom--PrepaidExpensesTextBlock_zziFEXy29iOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 2. <span id="xdx_82A_zIImWZF7Ie17">Prepaid Expenses</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid expenses and other current assets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zAFToehsI9If" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses (Details)"> <tr style="vertical-align: bottom"> <td style="display: none; text-align: left">Schedule of prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220331_zXJ47EMHIh7c" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20211231_zqLqPA7DeQta" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_400_ecustom--PrepaidStockOptionsForServices_iI_pp0p0_maPECzSWF_zc4xRdXjsBX" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 70%; text-align: left">Prepaid stock options for services</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">87,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">87,001</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--PrepaidProfessionalFees_iI_pp0p0_maPECzSWF_zoiqvObrQbP1" style="vertical-align: bottom"> <td style="text-align: left">Prepaid professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626,126</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,930</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PrepaidResearchAndDevelopmentExpense_iI_pp0p0_maPECzSWF_zvDGWfPeJRfh" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left">Prepaid research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173,124</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,746</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzSWF_zj0kpVwaqmSg" style="vertical-align: bottom"> <td style="text-align: left">Other prepaid costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,747</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--RefundsDue_iI_pp0p0_maPECzSWF_zCxU7HnbGJI" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left; padding-bottom: 1pt">Refunds due</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,804</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtPECzSWF_zxXL48guaiV6" style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.25pt">Total prepaid expenses</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">905,997</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">533,445</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zAFToehsI9If" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses (Details)"> <tr style="vertical-align: bottom"> <td style="display: none; text-align: left">Schedule of prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220331_zXJ47EMHIh7c" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20211231_zqLqPA7DeQta" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_400_ecustom--PrepaidStockOptionsForServices_iI_pp0p0_maPECzSWF_zc4xRdXjsBX" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 70%; text-align: left">Prepaid stock options for services</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">87,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">87,001</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--PrepaidProfessionalFees_iI_pp0p0_maPECzSWF_zoiqvObrQbP1" style="vertical-align: bottom"> <td style="text-align: left">Prepaid professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626,126</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,930</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PrepaidResearchAndDevelopmentExpense_iI_pp0p0_maPECzSWF_zvDGWfPeJRfh" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left">Prepaid research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173,124</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289,746</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzSWF_zj0kpVwaqmSg" style="vertical-align: bottom"> <td style="text-align: left">Other prepaid costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,747</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--RefundsDue_iI_pp0p0_maPECzSWF_zCxU7HnbGJI" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left; padding-bottom: 1pt">Refunds due</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">41,804</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtPECzSWF_zxXL48guaiV6" style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 2.25pt">Total prepaid expenses</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">905,997</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">533,445</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> 87000 87001 626126 100930 173124 289746 19747 13964 41804 905997 533445 <p id="xdx_80D_ecustom--RelatedPartyConvertiblePromissoryNoteTextBlock_z2AXA5cv0qMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3. <span><span id="xdx_822_zvDqmca4FvB4">Related Party Convertible Promissory Note</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: -0.35pt">On March 18, 2022, the Company issued an Unsecured Convertible Promissory Note (the “<b>Unsecured Note</b>”) to Kalen Capital. Pursuant to the terms of the Unsecured Note, Kalen Capital loaned the Company $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220318__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_zPIjZNzV5eD6" title="Loan">800,000</span> at an annual interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220301__20220318__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_zO7CTGFKRjnl" title="Interest rate">1</span>% per year, compounded daily. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Unsecured Note, and any balance thereunder, automatically converts into securities of the Company upon receipt of an equity financing from third-party(s) of not less than ten million dollars ($10,000,000) at a conversion price equal to 80% of the price paid in such a financing. Also, after June 23, 2023, Kalen Capital may convert all or any portion of the balance into shares of common stock at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20220318__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KalenCapitalCorpMember_pdd" title="Conversion price">0.45</span> per share, representing a fifty 50% percent premium to the closing price of the Company’s common stock on March 17, 2022. There is no commitment from Kalen Capital for any additional funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: -0.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended March 31, 2022, the Company recognized $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_c20220101__20220331_z22PN8bvMu6b" title="Interest expense">289</span> of interest expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b> </b></span></p> 800000 0.01 0.45 289 <p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zp5iONacaH6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 4. <span id="xdx_820_zT2t2e31ERDh">Accounts Payable and Accrued Liabilities</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts payable and accrued expenses consists of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRNbyEH78Sck" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Payable and Accrued Liabilities (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8BF_zcy1r3pzm2xk" style="display: none">Schedule of accounts payable and accrued expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220331" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zpWRCdtgK00e" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center"><p style="margin: 0pt 0; font-size: 10pt">March 31,</p></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 70%; text-align: left">Legal fees and related</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,176,033</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">869,950</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedOfficerCompensation_iI_pp0p0" style="vertical-align: bottom"> <td style="text-align: left">Officer compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">-</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,040</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedConsultants_iI_pp0p0" style="vertical-align: bottom; background-color: #DBE5F1"> <td>Consultants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,679</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,943</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedTradePayables_iI_pp0p0" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Trade payables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">188,139</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">231,815</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">1,369,851</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">1,274,748</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zRNbyEH78Sck" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Payable and Accrued Liabilities (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8BF_zcy1r3pzm2xk" style="display: none">Schedule of accounts payable and accrued expenses</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220331" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20211231_zpWRCdtgK00e" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center"><p style="margin: 0pt 0; font-size: 10pt">March 31,</p></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 70%; text-align: left">Legal fees and related</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,176,033</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">869,950</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedOfficerCompensation_iI_pp0p0" style="vertical-align: bottom"> <td style="text-align: left">Officer compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">-</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,040</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedConsultants_iI_pp0p0" style="vertical-align: bottom; background-color: #DBE5F1"> <td>Consultants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,679</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,943</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedTradePayables_iI_pp0p0" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Trade payables</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">188,139</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">231,815</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">1,369,851</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">1,274,748</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> 1176033 869950 55040 5679 117943 188139 231815 1369851 1274748 <p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z81CfZ2EOU7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 5. <span id="xdx_82C_zQvNIE4Pl7pl">Equity</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, the Company had <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_zht11M42bOWg" title="Common stock, Authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zQdp1dtgWBi8" title="Common stock, Authorized">500,000,000</span></span> authorized shares of common stock with a par value of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_zuN7VpR2P3X3" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zqXWiH0RGhUd" title="Common stock, par value">0.00001</span></span> per share and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20220331_z4oV00vy8ED1" title="Common stock, shares Issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zYpo4FXOK1K2" title="Common stock, shares outstanding"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20211231_zNEAr4qNGSc4" title="Common stock, shares Issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zrTQuiuqohXi" title="Common stock, shares outstanding">87,352,364</span></span></span></span> shares of common stock outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i/></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued warrants to purchase common stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information about warrants outstanding at March 31, 2022 and December 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock_z8p8MgeOohL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_zuEyWnN6xyIj" style="display: none">Schedule of warrants outstanding</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Shares of Common Stock Issuable from <br/> Warrants Outstanding as of</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td> <td style="text-align: center; white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><b>March 31,</b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><b>December 31,</b></td><td style="text-align: center"><b> </b></td> <td colspan="3" style="text-align: center; white-space: nowrap"><b>Average</b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><b>Description</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>2022</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1pt; text-align: center"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><b>Exercise Price</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><b> </b></td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><b>Expiration</b></td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 27%; text-align: left">Series F</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="width: 12%; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="width: 12%; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">7,246</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Weighted Average Exercise Price">3.45</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 27%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MinimumMember" title="Expiration">February 23, 2022</span> &amp; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MaximumMember" title="Expiration">March 9, 2022</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Series G</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Weighted Average Exercise Price">2.68</span></span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember" title="Expiration">July 21, 2022</span></td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left">Series H</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Weighted Average Exercise Price">2.75</span></span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember" title="Expiration">October 16, 2022</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Series I</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Weighted Average Exercise Price">2.00</span></span></td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember" title="Expiration">November 26, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">11,705,250</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">12,296,912</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="padding-bottom: 2.25pt"> </td></tr> </table> <p id="xdx_8A2_zvKvXjXOv6c1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2022, all the Series F Warrants expired unexercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock option activity for the three months ended March 31, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNz2RJD44pl8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 1)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zb4T7yESFmt" style="display: none">Schedule of stock option activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Options granted"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Options granted"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of <br/> Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value ($)</td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 48%">Outstanding at December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_zXxqW1cyUHml" style="width: 10%; text-align: right" title="Options outstanding - beginning balance">5,895,570</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zNohYzBxvjIk" style="width: 10%; text-align: right" title="Options outstanding - beginning balance">2.45</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_pdd" style="text-align: right" title="Options granted">50,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210930_pdd" style="text-align: right" title="Options granted">1.72</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210930_zY9qr0c4JcW1" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited">(2,805,571</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210930_pdd" style="text-align: right" title="Options forfeited">2.74</td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding at September 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220331_z0KkvFRot1Fe" style="text-align: right" title="Options outstanding - beginning balance">3,139,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220331_zRx2ApJLjJx3" style="text-align: right" title="Options outstanding - beginning balance">2.17</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220331_z4ofuGq1ybr4" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited">(40,000</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220331_zC0yJ82vPLj8" style="text-align: right" title="Options forfeited">1.79</td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding at March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220331_zDYqFYIS3OG7" style="text-align: right" title="Options oustanding - ending balance">3,099,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220331_zMbjHSh4qbFd" style="text-align: right" title="Options outstanding - ending balance">2.17</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220331_zMBIB3GN4SQ9" style="text-align: right" title="Weighted average remaining contracted term">4.30</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20220331_pp0p0" style="text-align: right" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left">Vested and exercisable at March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220331_pdd" style="text-align: right" title="Options Vested and Exercisable">2,699,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220331_pdd" style="text-align: right" title="Options Vested and Exercisable">2.02</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20211001__20220331_z5ETewGdrS1b" title="Options Vested and Exercisable">4.30</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220331_pp0p0" style="text-align: right" title="Options Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0555">-</span></td><td style="white-space: nowrap; text-align: left"> </td></tr> </table> <p id="xdx_8A0_ztXyGbXu9Mxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three months ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_z9vIUr7GfQ7g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_86A_zktnMI2eoSae" style="display: none">Schedule of consolidated statement of operations</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; text-align: right" title="Total">217,500</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; text-align: right" title="Total">278,815</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">5,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">(1,153,575</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20220331_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total">223,000</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210331_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total">(874,760</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 500000000 500000000 0.00001 0.00001 87352364 87352364 87352364 87352364 <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock_z8p8MgeOohL9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B9_zuEyWnN6xyIj" style="display: none">Schedule of warrants outstanding</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Shares of Common Stock Issuable from <br/> Warrants Outstanding as of</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted</b></td><td style="text-align: center; padding-bottom: 1pt"><b> </b></td> <td style="text-align: center; white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><b>March 31,</b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"><b>December 31,</b></td><td style="text-align: center"><b> </b></td> <td colspan="3" style="text-align: center; white-space: nowrap"><b>Average</b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><b>Description</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>2022</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1pt; text-align: center"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><b>Exercise Price</b></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><b> </b></td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><b>Expiration</b></td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 27%; text-align: left">Series F</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="width: 12%; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="width: 12%; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">7,246</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" title="Weighted Average Exercise Price">3.45</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 27%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MinimumMember" title="Expiration">February 23, 2022</span> &amp; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MaximumMember" title="Expiration">March 9, 2022</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Series G</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" title="Weighted Average Exercise Price">2.68</span></span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember" title="Expiration">July 21, 2022</span></td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left">Series H</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" title="Weighted Average Exercise Price">2.75</span></span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember" title="Expiration">October 16, 2022</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Series I</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Weighted Average Exercise Price"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" title="Weighted Average Exercise Price">2.00</span></span></td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember" title="Expiration">November 26, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">11,705,250</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20211231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.25pt double; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">12,296,912</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="padding-bottom: 2.25pt"> </td></tr> </table> 7246 3.45 3.45 2022-02-23 2022-03-09 460250 460250 2.68 2.68 2022-07-21 910000 910000 2.75 2.75 2022-10-16 10335000 10335000 2.00 2.00 2025-11-26 11705250 12296912 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNz2RJD44pl8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 1)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zb4T7yESFmt" style="display: none">Schedule of stock option activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Options granted"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Options granted"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of <br/> Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value ($)</td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="width: 48%">Outstanding at December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_zXxqW1cyUHml" style="width: 10%; text-align: right" title="Options outstanding - beginning balance">5,895,570</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210930_zNohYzBxvjIk" style="width: 10%; text-align: right" title="Options outstanding - beginning balance">2.45</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_pdd" style="text-align: right" title="Options granted">50,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210930_pdd" style="text-align: right" title="Options granted">1.72</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210930_zY9qr0c4JcW1" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited">(2,805,571</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210930_pdd" style="text-align: right" title="Options forfeited">2.74</td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding at September 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220331_z0KkvFRot1Fe" style="text-align: right" title="Options outstanding - beginning balance">3,139,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220331_zRx2ApJLjJx3" style="text-align: right" title="Options outstanding - beginning balance">2.17</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220331_z4ofuGq1ybr4" style="border-bottom: Black 1pt solid; text-align: right" title="Options forfeited">(40,000</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220331_zC0yJ82vPLj8" style="text-align: right" title="Options forfeited">1.79</td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding at March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20220331_zDYqFYIS3OG7" style="text-align: right" title="Options oustanding - ending balance">3,099,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20220331_zMbjHSh4qbFd" style="text-align: right" title="Options outstanding - ending balance">2.17</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220331_zMBIB3GN4SQ9" style="text-align: right" title="Weighted average remaining contracted term">4.30</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20220331_pp0p0" style="text-align: right" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #DBE5F1"> <td style="text-align: left">Vested and exercisable at March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220331_pdd" style="text-align: right" title="Options Vested and Exercisable">2,699,999</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20220331_pdd" style="text-align: right" title="Options Vested and Exercisable">2.02</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20211001__20220331_z5ETewGdrS1b" title="Options Vested and Exercisable">4.30</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20220331_pp0p0" style="text-align: right" title="Options Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0555">-</span></td><td style="white-space: nowrap; text-align: left"> </td></tr> </table> 5895570 2.45 50000 1.72 2805571 2.74 3139999 2.17 40000 1.79 3099999 2.17 P4Y3M18D 2699999 2.02 P4Y3M18D <table cellpadding="0" cellspacing="0" id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_z9vIUr7GfQ7g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_86A_zktnMI2eoSae" style="display: none">Schedule of consolidated statement of operations</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; text-align: right" title="Total">217,500</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; text-align: right" title="Total">278,815</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">5,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">(1,153,575</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20220101__20220331_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total">223,000</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210331_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total">(874,760</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 217500 278815 5500 -1153575 223000 -874760 <p id="xdx_806_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zaL1qWkcI0H9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 6. <span id="xdx_82D_z8R9XsKSLa03">Leases</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt">In February 2020, the Company entered into a two-year lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey (the “Premises”). Monthly base rent in year one of the lease is $<span id="xdx_902_ecustom--BaseRentForFirstYear_c20220101__20220331_pp0p0" title="Base rent for First year">4,356</span>; and $<span id="xdx_90A_ecustom--BaseRentForSecondYear_c20220101__20220331_pp0p0" title="Base rent for Second year">4,459</span> in year <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20220331_zZHkovSC6mgk" title="Lease term">2</span> of the lease. The term (and payment of the monthly rent) commenced upon completion of the landlord’s work on August 1, 2020. The Company vacated the premises in May of 2021 and relocated its corporate offices to 9375 E. Shea Blvd., Suite 107-A, Scottsdale, AZ 85260.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s existing lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company does not have any finance leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Supplemental lease information:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z0pmSxbiiMbh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"><span id="xdx_8BC_z5ZYB3JwfVy4" style="display: none">Schedule of supplemental lease information</span></td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">As of March 31,</td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">As of December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: justify">Operating lease right-of-use asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_c20220331_pp0p0" style="width: 12%; text-align: right" title="Operating lease right-of-use asset">15,866</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_c20211231_pp0p0" style="width: 12%; text-align: right" title="Operating lease right-of-use asset">28,630</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: justify">Current maturities of operating lease</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20220331_pp0p0" style="text-align: right" title="Current maturities of operating lease">17,578</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_c20211231_pp0p0" style="text-align: right" title="Current maturities of operating lease">30,497</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Current maturities of operating lease in accounts payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--CurrentMaturitiesOfOperatingLeaseInAccountsPayable_iI_pp0p0_c20220331_ze6PwMtDxzci" style="border-bottom: Black 1pt solid; text-align: right" title="Current maturities of operating lease in accounts payable">8,918</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--CurrentMaturitiesOfOperatingLeaseInAccountsPayable_iI_pp0p0_c20211231_z9oTATItEPm7" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.25pt">Total operating lease liabilities</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20220331_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total operating lease liabilities">26,496</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_c20211231_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total operating lease liabilities">30,497</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted Average remaining lease term (in years):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zjzlh82fzMk1" title="Weighted Average remaining lease term (in years):">0.34</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zVAJRJZvb7P2" title="Weighted Average remaining lease term (in years):">0.58</span></td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left">Right-of-use asset obtained in exchange for lease obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20220101__20220331_zMkWEdcqcOH1" style="color: rgb(217,225,242); text-align: right" title="Right-of-use asset obtained in exchange for lease obligation"><span style="-sec-ix-hidden: xdx2ixbrl0600">-</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210101__20210331_pp0p0" style="text-align: right" title="Right-of-use asset obtained in exchange for lease obligation"><p style="margin: 0pt 0; font-size: 10pt">98,405</p></td><td style="white-space: nowrap; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental information for the three months ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: justify">Cash paid for amount included in the measurement of lease liabilities for operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePaymentsUse_c20220101__20220331_pp0p0" style="width: 12%; text-align: right" title="Cash paid for amount included in the measurement of lease liabilities for operating lease">4,459</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeasePaymentsUse_c20210101__20210331_pp0p0" style="width: 12%; text-align: right" title="Cash paid for amount included in the measurement of lease liabilities for operating lease">13,068</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zK8z7Ac9Jkf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases office space under a non-cancellable operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at March 31, 2022 for future periods are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z0FSGg5TH35h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8BB_zjsIX8FB0iyk" style="display: none">Schedule of future lease payments</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_497_20220331_zmVlpGfNhPfk" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPzKCH_zzAsjjGgnNtb" style="vertical-align: bottom; background-color: white"> <td style="width: 85%; text-align: left; padding-bottom: 1pt">2022</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,754</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_pp0p0_mtOLFMPzKCH_zjkkzm5Pbdva" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,754</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--Total_iI_pp0p0_zXmt8T8yHSpb" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">26,216</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z262BN9WTUe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 4356 4459 P2Y <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z0pmSxbiiMbh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"><span id="xdx_8BC_z5ZYB3JwfVy4" style="display: none">Schedule of supplemental lease information</span></td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">As of March 31,</td><td style="font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">As of December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: justify">Operating lease right-of-use asset</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_c20220331_pp0p0" style="width: 12%; text-align: right" title="Operating lease right-of-use asset">15,866</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_c20211231_pp0p0" style="width: 12%; text-align: right" title="Operating lease right-of-use asset">28,630</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: justify">Current maturities of operating lease</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_c20220331_pp0p0" style="text-align: right" title="Current maturities of operating lease">17,578</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_c20211231_pp0p0" style="text-align: right" title="Current maturities of operating lease">30,497</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Current maturities of operating lease in accounts payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--CurrentMaturitiesOfOperatingLeaseInAccountsPayable_iI_pp0p0_c20220331_ze6PwMtDxzci" style="border-bottom: Black 1pt solid; text-align: right" title="Current maturities of operating lease in accounts payable">8,918</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--CurrentMaturitiesOfOperatingLeaseInAccountsPayable_iI_pp0p0_c20211231_z9oTATItEPm7" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.25pt">Total operating lease liabilities</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_c20220331_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total operating lease liabilities">26,496</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_c20211231_pp0p0" style="border-bottom: Black 2.25pt double; text-align: right" title="Total operating lease liabilities">30,497</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted Average remaining lease term (in years):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zjzlh82fzMk1" title="Weighted Average remaining lease term (in years):">0.34</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zVAJRJZvb7P2" title="Weighted Average remaining lease term (in years):">0.58</span></td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left">Right-of-use asset obtained in exchange for lease obligation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20220101__20220331_zMkWEdcqcOH1" style="color: rgb(217,225,242); text-align: right" title="Right-of-use asset obtained in exchange for lease obligation"><span style="-sec-ix-hidden: xdx2ixbrl0600">-</span></td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210101__20210331_pp0p0" style="text-align: right" title="Right-of-use asset obtained in exchange for lease obligation"><p style="margin: 0pt 0; font-size: 10pt">98,405</p></td><td style="white-space: nowrap; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental information for the three months ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="width: 70%; text-align: justify">Cash paid for amount included in the measurement of lease liabilities for operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePaymentsUse_c20220101__20220331_pp0p0" style="width: 12%; text-align: right" title="Cash paid for amount included in the measurement of lease liabilities for operating lease">4,459</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeasePaymentsUse_c20210101__20210331_pp0p0" style="width: 12%; text-align: right" title="Cash paid for amount included in the measurement of lease liabilities for operating lease">13,068</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> </table> 15866 28630 17578 30497 8918 26496 30497 P0Y4M2D P0Y6M29D 98405 4459 13068 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z0FSGg5TH35h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8BB_zjsIX8FB0iyk" style="display: none">Schedule of future lease payments</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_497_20220331_zmVlpGfNhPfk" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPzKCH_zzAsjjGgnNtb" style="vertical-align: bottom; background-color: white"> <td style="width: 85%; text-align: left; padding-bottom: 1pt">2022</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,754</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_pp0p0_mtOLFMPzKCH_zjkkzm5Pbdva" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,754</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--Total_iI_pp0p0_zXmt8T8yHSpb" style="vertical-align: bottom; background-color: rgb(217,225,242)"> <td style="padding-bottom: 2.25pt">Total</td><td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">26,216</td><td style="border-bottom: Black 2.25pt double; white-space: nowrap; text-align: left"> </td></tr> </table> 26754 26754 -538 26216 <p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zduqF0XBfWr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 7. <span id="xdx_828_zvc8D6FaBcD3">Commitments and Contingencies</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stem Cell Systems</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s anticipated future regulatory filings, the Company has engaged StemCell Systems GmbH (“<b>StemCell Systems</b>”) to provide it with medical device prototypes and related design documents and data under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&amp;D Agreement (the “<b>Strategic Agreement</b>”) having an initial term of three years with successive one-year extensions unless earlier terminated. The Strategic Agreement includes a $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StemCellSystemsMember_zCsxqVJbfe98" title="Periodic Payment">39,000</span> monthly fee to be paid to StemCell Systems along with any additional expenses incurred. The Company, StemCell Systems and certain affiliates of StemCell Systems entered into a Rights of First Refusal and Corporate Opportunities Agreement (the “<b>ROFR Agreement</b>”). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Company’s acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of $<span id="xdx_902_eus-gaap--CostsAndExpenses_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StemCellSystemsMember_pp0p0" title="Incurred expenses">125,931</span> and $<span id="xdx_90B_eus-gaap--CostsAndExpenses_c20210101__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StemCellSystemsMember_pp0p0" title="Incurred expenses">120,377</span> during the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the Company had a balance due to StemCell Systems of $<span id="xdx_90E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StemCellSystemsMember_z5siYrOeF2ic" title="Due to related party">83,700</span>. On April 28, 2022 the Company provided StemCell Systems with notice of termination of the Strategic Agreement. See “Note 8. Subsequent Events.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><b><i>SEC Civil Complaint </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 28, 2021 the SEC filed a civil complaint (the “<b>SEC Action</b>”), in the United States District Court for the Southern District of New York, naming the Company and Harmel S. Rayat, the Company’s current President, Chief Executive Officer, Chief Financial Officer and Sole Director as defendants (the “<b>Defendants</b>”). The SEC Action alleges among other things that Mr. Rayat and the Company with violated the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also alleges that Mr. Rayat aided and abetted the violations of those provisions by the Company. The SEC Action also alleges that the Company violated the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks, among other relief, permanent injunctions and civil penalties against the Defendants, and officer-and-director and penny stock bars against Mr. Rayat. On August 31, 2021 the Defendants filed an answer to the Complaint. On September 21, 2021, the SEC filed a motion to strike Defendants equitable affirmative defenses which motion was granted by the court on October 18, 2021. The Company continues to defend itself and the named individuals against the allegations set forth in the SEC Action. Due to the nature and early stage of the SEC Action, the Company is unable to estimate the total costs to defend itself or the potential costs to the Company in the event that it is not successful in its defense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Class Action Complaints</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, Gabrielle A. Boller filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the “<b>Boller Lawsuit</b>”), against the Company and certain past and current officers and members of the Company’s board of directors (collectively, the “<b>Boller Defendants</b>”). The Boller Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the SEC Action, the Boller Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Boller Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred in the Boller Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes the plaintiffs’ claims in the Boller Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Boller Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2021, Michael Solakian, filed a class action lawsuit in the U.S. District Court for the District of New Jersey (the “<b>Solakian Lawsuit</b>”), against the Company and certain past and current officers and members of the Company’s board of directors (collectively, the “<b>Solakian Defendants</b>”). The Solakian Lawsuit alleges, among other things, that in connection with the facts and circumstances underlying the allegations in the SEC Action, the Solakian Defendants engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. The plaintiff seeks a determination that the Solakian Lawsuit is a proper class action, compensatory damages in favor of the plaintiff and other class members, reasonable costs and expenses incurred in the Solakian Lawsuit, including counsel fees and expert fees, and such other relief as the Court may deem proper.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes the plaintiffs’ claims in the Solakian Lawsuit and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Solakian Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i/></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><b><i>Shareholder Derivative Complaints</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, Melvin Emberland (“Emberland”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “<b>Emberland Lawsuit</b>”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “<b>Emberland Defendants</b>”). In the complaint, Emberland’s allegations, relating to the facts and circumstances underlying the allegations in the SEC Action include, but are not limited to (i) breach of fiduciary duties by the individual Emberland Defendants, (ii) unjust enrichment and (iii) violation of Section 10(b) and 21D of the Securities Exchange Act of 1934. Emberland did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Emberland seeks (i) a declaration that the Emberland Defendants have breached and/or aided and abetted the breach of their fiduciary duties to the Company, (ii) a determination awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Emberland Defendants, (iii) a directive to the Company and the Emberland Defendants to take all necessary actions to reform and improve the Company’s corporate governance and internal procedures to comply with applicable laws, and (iv) Plaintiff is seeking, among other things, restitution from the individual Emberland Defendants and disgorgement of profits, benefits and other compensation obtained by such Emberland Defendants, costs and disbursements of the action including reasonable attorney’s fees, accountants’ and expert fees and expenses, an order directing the taking of certain corporate actions relating to its board of directors and corporate governance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes Emberland’s claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Emberland Defendants. Given the uncertainty of litigation, the preliminary stage of the Emberland Lawsuit, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2022, Zoser Vargas (“<b>Vargas</b>”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “<b>Vargas Lawsuit</b>”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “<b>Vargas Defendants</b>”). In the complaint Vargas’ allegations relating to the facts and circumstances underlying the allegations in the SEC Action include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Meyer seeks, in addition to other things, (i) against the Vargas Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the Vargas Defendants’ breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Vargas Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Vargas Defendants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes Vargas’ claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Vargas Defendants. Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, Aviva Meyer (“<b>Meyer</b>”), derivatively and on behalf of nominal defendant Renovacare, Inc. filed a lawsuit (the “<b>Meyer Lawsuit</b>”) in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (the “<b>Meyer Defendants</b>”). In the complaint Meyer’s allegations relating to the facts and circumstances underlying the allegations in the SEC Action include but are not limited to, (i) breach of fiduciary duties, (ii) waste of corporate assets, (iii) violation of law, and (iii) unjust enrichment. Vargas did not quantify any alleged damages in his complaint but, in addition to attorneys’ fees and costs, Meyer seeks, in addition to other things, (i) against the <b>Vargas</b> Defendants and in favor of the Company the amount of damages sustained by the Company as a result of the <b>Vargas</b> Defendants’ breaches of fiduciary duties, waste of corporate assets and unjust enrichment, (ii) directive for the Company to take all necessary actions to improve its corporate governance and internal procedures to comply with applicable law and (iii) awarding to the Company restitution from the Meyer Defendants, and each of them, and ordering disgorgement of all profits, benefits and other compensation obtained by the Meyer Defendants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disputes Meyer’s claims and intends to defend these matters vigorously. To that end, the Company has engaged counsel to defend the Meyer Defendants Given the uncertainty of litigation, the preliminary stage of these cases, the legal standards that must be met for success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify">The Company believes that the claims asserted in the SEC Action, the Boller Lawsuit, the Solakian Lawsuit, the Emberland Lawsuit, the Vargas Lawsuit, and the Meyer Lawsuit (collectively, the “<b>Lawsuits</b>”) are without merit and intends to vigorously defend each Lawsuit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 39000 125931 120377 83700 <p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_z0cxtE9lTra4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 8. <span id="xdx_82D_zhc396yUyVIa">Subsequent Events</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has reviewed material events subsequent of the period ended March 31, 2022 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2022, the Company made retainer payments to its attorneys in the amount of $<span id="xdx_907_ecustom--PaymentsToRetainer_c20220401__20220421__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--AttorneysMember_zhyA3mqZpx6a" title="Payments to retainer">1,180,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 28, 2022, the Company terminated the Strategic Agreement with StemCell Systems.</p> 1180000 EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 60 155 1 false 20 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://renovacareinc.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://renovacareinc.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://renovacareinc.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share Sheet http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShare Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share Notes 7 false false R8.htm 00000008 - Disclosure - Prepaid Expenses Sheet http://renovacareinc.com/role/PrepaidExpenses Prepaid Expenses Notes 8 false false R9.htm 00000009 - Disclosure - Related Party Convertible Promissory Note Sheet http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNote Related Party Convertible Promissory Note Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 10 false false R11.htm 00000011 - Disclosure - Equity Sheet http://renovacareinc.com/role/Equity Equity Notes 11 false false R12.htm 00000012 - Disclosure - Leases Sheet http://renovacareinc.com/role/Leases Leases Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://renovacareinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://renovacareinc.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Policies) Sheet http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Policies) Policies http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShare 15 false false R16.htm 00000016 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Tables) Sheet http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareTables Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Tables) Tables http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShare 16 false false R17.htm 00000017 - Disclosure - Prepaid Expenses (Tables) Sheet http://renovacareinc.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://renovacareinc.com/role/PrepaidExpenses 17 false false R18.htm 00000018 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilities 18 false false R19.htm 00000019 - Disclosure - Equity (Tables) Sheet http://renovacareinc.com/role/EquityTables Equity (Tables) Tables http://renovacareinc.com/role/Equity 19 false false R20.htm 00000020 - Disclosure - Leases (Tables) Sheet http://renovacareinc.com/role/LeasesTables Leases (Tables) Tables http://renovacareinc.com/role/Leases 20 false false R21.htm 00000021 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details) Sheet http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details) Details http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareTables 21 false false R22.htm 00000022 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative) Sheet http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative) Details http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareTables 22 false false R23.htm 00000023 - Disclosure - Prepaid Expenses (Details) Sheet http://renovacareinc.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://renovacareinc.com/role/PrepaidExpensesTables 23 false false R24.htm 00000024 - Disclosure - Related Party Convertible Promissory Note (Details Narrative) Sheet http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative Related Party Convertible Promissory Note (Details Narrative) Details http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNote 24 false false R25.htm 00000025 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesTables 25 false false R26.htm 00000026 - Disclosure - Equity (Details) Sheet http://renovacareinc.com/role/EquityDetails Equity (Details) Details http://renovacareinc.com/role/EquityTables 26 false false R27.htm 00000027 - Disclosure - Equity (Details 1) Sheet http://renovacareinc.com/role/EquityDetails1 Equity (Details 1) Details http://renovacareinc.com/role/EquityTables 27 false false R28.htm 00000028 - Disclosure - Equity (Details 2) Sheet http://renovacareinc.com/role/EquityDetails2 Equity (Details 2) Details http://renovacareinc.com/role/EquityTables 28 false false R29.htm 00000029 - Disclosure - Equity (Details Narrative) Sheet http://renovacareinc.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://renovacareinc.com/role/EquityTables 29 false false R30.htm 00000030 - Disclosure - Leases (Details) Sheet http://renovacareinc.com/role/LeasesDetails Leases (Details) Details http://renovacareinc.com/role/LeasesTables 30 false false R31.htm 00000031 - Disclosure - Leases (Details 1) Sheet http://renovacareinc.com/role/LeasesDetails1 Leases (Details 1) Details http://renovacareinc.com/role/LeasesTables 31 false false R32.htm 00000032 - Disclosure - Leases (Details Narrative) Sheet http://renovacareinc.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://renovacareinc.com/role/LeasesTables 32 false false R33.htm 00000033 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://renovacareinc.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - Subsequent Events (Details Narrative) Sheet http://renovacareinc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://renovacareinc.com/role/SubsequentEvents 34 false false All Reports Book All Reports f10q_051022p.htm exh_311.htm exh_321.htm rcar-20220331.xsd rcar-20220331_cal.xml rcar-20220331_def.xml rcar-20220331_lab.xml rcar-20220331_pre.xml http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q_051022p.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 60, "dts": { "calculationLink": { "local": [ "rcar-20220331_cal.xml" ] }, "definitionLink": { "local": [ "rcar-20220331_def.xml" ] }, "inline": { "local": [ "f10q_051022p.htm" ] }, "labelLink": { "local": [ "rcar-20220331_lab.xml" ] }, "presentationLink": { "local": [ "rcar-20220331_pre.xml" ] }, "schema": { "local": [ "rcar-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 264, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 18, "http://renovacareinc.com/20220331": 10, "http://xbrl.sec.gov/dei/2022": 5, "total": 33 }, "keyCustom": 26, "keyStandard": 129, "memberCustom": 8, "memberStandard": 11, "nsprefix": "rcar", "nsuri": "http://renovacareinc.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://renovacareinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Equity", "role": "http://renovacareinc.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Leases", "role": "http://renovacareinc.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Commitments and Contingencies", "role": "http://renovacareinc.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Subsequent Events", "role": "http://renovacareinc.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Policies)", "role": "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies", "shortName": "Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Tables)", "role": "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareTables", "shortName": "Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "rcar:PrepaidExpensesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Prepaid Expenses (Tables)", "role": "http://renovacareinc.com/role/PrepaidExpensesTables", "shortName": "Prepaid Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "rcar:PrepaidExpensesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "rcar:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Equity (Tables)", "role": "http://renovacareinc.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "rcar:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://renovacareinc.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Leases (Tables)", "role": "http://renovacareinc.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details)", "role": "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails", "shortName": "Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "lang": null, "name": "rcar:WeightedAverageNumberOfCommonSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "b", "span", "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationStateCountryCode", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative)", "role": "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "shortName": "Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "rcar:OrganizationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "rcar:PrepaidExpensesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "rcar:PrepaidStockOptionsForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Prepaid Expenses (Details)", "role": "http://renovacareinc.com/role/PrepaidExpensesDetails", "shortName": "Prepaid Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "rcar:PrepaidExpensesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "rcar:PrepaidStockOptionsForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "rcar:RelatedPartyConvertiblePromissoryNoteTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Related Party Convertible Promissory Note (Details Narrative)", "role": "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative", "shortName": "Related Party Convertible Promissory Note (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "rcar:RelatedPartyConvertiblePromissoryNoteTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "role": "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "rcar:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2021-12-31_custom_SeriesFMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Equity (Details)", "role": "http://renovacareinc.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "rcar:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2021-12-31_custom_SeriesFMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Equity (Details 1)", "role": "http://renovacareinc.com/role/EquityDetails1", "shortName": "Equity (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Equity (Details 2)", "role": "http://renovacareinc.com/role/EquityDetails2", "shortName": "Equity (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Equity (Details Narrative)", "role": "http://renovacareinc.com/role/EquityDetailsNarrative", "shortName": "Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Leases (Details)", "role": "http://renovacareinc.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "rcar:CurrentMaturitiesOfOperatingLeaseInAccountsPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Leases (Details 1)", "role": "http://renovacareinc.com/role/LeasesDetails1", "shortName": "Leases (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "rcar:BaseRentForFirstYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Leases (Details Narrative)", "role": "http://renovacareinc.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "rcar:BaseRentForFirstYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-012022-03-31_custom_StemCellSystemsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-012022-03-31_custom_StemCellSystemsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-012022-03-31_custom_AttorneysMember", "decimals": "0", "first": true, "lang": null, "name": "rcar:PaymentsToRetainer", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-04-012022-04-21_us-gaap_SubsequentEventMember_custom_AttorneysMember", "decimals": "0", "lang": null, "name": "rcar:PaymentsToRetainer", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "role": "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share", "role": "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShare", "shortName": "Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "rcar:PrepaidExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Prepaid Expenses", "role": "http://renovacareinc.com/role/PrepaidExpenses", "shortName": "Prepaid Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "rcar:PrepaidExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "rcar:RelatedPartyConvertiblePromissoryNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Related Party Convertible Promissory Note", "role": "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNote", "shortName": "Related Party Convertible Promissory Note", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "f10q_051022p.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "rcar:RelatedPartyConvertiblePromissoryNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 20, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r325", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Date of Incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://renovacareinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "rcar_AccruedConsultants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consultants" } } }, "localname": "AccruedConsultants", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_AccruedOfficerCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Officer compensation" } } }, "localname": "AccruedOfficerCompensation", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_AccruedTradePayables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Trade payables" } } }, "localname": "AccruedTradePayables", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_AttorneysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Attorneys [Member]" } } }, "localname": "AttorneysMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rcar_BaseRentForFirstYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Base rent for First year" } } }, "localname": "BaseRentForFirstYear", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rcar_BaseRentForSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Base rent for Second year" } } }, "localname": "BaseRentForSecondYear", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rcar_BasicAndDilutedEps": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted EPS" } } }, "localname": "BasicAndDilutedEps", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "rcar_BasicAndDilutedEpsComputationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted EPS Computation" } } }, "localname": "BasicAndDilutedEpsComputationAbstract", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "rcar_BasicAndDilutedLossPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss per Common Share" } } }, "localname": "BasicAndDilutedLossPerCommonShare", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "rcar_CurrentMaturitiesOfOperatingLeaseInAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current maturities of operating lease in accounts payable" } } }, "localname": "CurrentMaturitiesOfOperatingLeaseInAccountsPayable", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "rcar_DisclosurePrepaidExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses" } } }, "localname": "DisclosurePrepaidExpensesAbstract", "nsuri": "http://renovacareinc.com/20220331", "xbrltype": "stringItemType" }, "rcar_DisclosureRelatedPartyConvertiblePromissoryNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Convertible Promissory Note" } } }, "localname": "DisclosureRelatedPartyConvertiblePromissoryNoteAbstract", "nsuri": "http://renovacareinc.com/20220331", "xbrltype": "stringItemType" }, "rcar_GeneralAndAdministrative": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "General and administrative" } } }, "localname": "GeneralAndAdministrative", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "rcar_ImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "localname": "ImputedInterest", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "rcar_InterestPayableOnConvertiblePromissoryNoteToRelatedParty": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Interest payable on convertible promissory note to related party" } } }, "localname": "InterestPayableOnConvertiblePromissoryNoteToRelatedParty", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rcar_KalenCapitalCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kalen Capital Corp [Member]" } } }, "localname": "KalenCapitalCorpMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "rcar_KalenCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kalen Capital [Member]" } } }, "localname": "KalenCapitalMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "rcar_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcar_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "rcar_OrganizationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization" } } }, "localname": "OrganizationPolicyTextBlock", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies" ], "xbrltype": "textBlockItemType" }, "rcar_PaymentsToRetainer": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments to retainer" } } }, "localname": "PaymentsToRetainer", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rcar_PrepaidExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PrepaidExpensesTextBlock", "verboseLabel": "Prepaid Expenses" } } }, "localname": "PrepaidExpensesTextBlock", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/PrepaidExpenses" ], "xbrltype": "textBlockItemType" }, "rcar_PrepaidProfessionalFees": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/PrepaidExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid professional fees" } } }, "localname": "PrepaidProfessionalFees", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_PrepaidResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/PrepaidExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid research and development expense" } } }, "localname": "PrepaidResearchAndDevelopmentExpense", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_PrepaidStockOptionsForServices": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/PrepaidExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid stock options for services" } } }, "localname": "PrepaidStockOptionsForServices", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_RefundsDue": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/PrepaidExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Refunds due" } } }, "localname": "RefundsDue", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "rcar_RelatedPartyConvertiblePromissoryNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RelatedPartyConvertiblePromissoryNoteTextBlock", "verboseLabel": "Related Party Convertible Promissory Note" } } }, "localname": "RelatedPartyConvertiblePromissoryNoteTextBlock", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNote" ], "xbrltype": "textBlockItemType" }, "rcar_ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reversal of stock-based compensation due to common stock purchase option cancellations" } } }, "localname": "ReversalOfStockbasedCompensationDueToCommonStockPurchaseOptionCancellations", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "rcar_ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "rcar_SeriesFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series F [Member]" } } }, "localname": "SeriesFMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "rcar_SeriesGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series G [Member]" } } }, "localname": "SeriesGMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "rcar_SeriesHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series H [Member]" } } }, "localname": "SeriesHMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "rcar_SeriesIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series I [Member]" } } }, "localname": "SeriesIMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "rcar_StemCellSystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StemCell Systems [Member]" } } }, "localname": "StemCellSystemsMember", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rcar_StockBasedCompensationDueToCommonStockPurchaseOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock based compensation due to common stock purchase options" } } }, "localname": "StockBasedCompensationDueToCommonStockPurchaseOptions", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "rcar_Total": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total [Default Label]", "verboseLabel": "Total" } } }, "localname": "Total", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "rcar_WeightedAverageNumberOfCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstanding", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "rcar_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://renovacareinc.com/20220331", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r31", "r33", "r58", "r59", "r134", "r146", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r112", "r113", "r114", "r115", "r133", "r145", "r169", "r170", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r301", "r302", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r112", "r113", "r114", "r115", "r133", "r145", "r169", "r170", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r301", "r302", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r107", "r112", "r113", "r114", "r115", "r133", "r145", "r162", "r169", "r170", "r197", "r198", "r199", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r301", "r302", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r107", "r112", "r113", "r114", "r115", "r133", "r145", "r162", "r169", "r170", "r197", "r198", "r199", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r301", "r302", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r32", "r33", "r58", "r59", "r134", "r146" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r60", "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://renovacareinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities", "verboseLabel": "Total" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Legal fees and related" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r9", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r258" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r62", "r63", "r64", "r203", "r204", "r205", "r221" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash flows used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total shares not included in the computation of diluted losses per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r56", "r84", "r87", "r93", "r99", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r211", "r215", "r223", "r256", "r258", "r283", "r293" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r20", "r56", "r99", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r211", "r215", "r223", "r256", "r258" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r8", "r258", "r308", "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash on hand" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r8", "r54" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets", "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r49", "r224" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r160", "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r160", "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r286", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r109", "r110", "r111", "r116", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r62", "r63", "r221" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://renovacareinc.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://renovacareinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://renovacareinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://renovacareinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r258" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at March 31, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Incurred expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r132", "r137" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r131", "r139", "r140", "r233", "r235", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Loan" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r27", "r135", "r233" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r28", "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r52", "r103" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r57", "r121", "r123", "r124", "r128", "r129", "r130", "r253", "r285", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:" } } }, "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r36", "r37", "r38", "r62", "r63", "r64", "r66", "r71", "r73", "r79", "r100", "r158", "r159", "r203", "r204", "r205", "r207", "r208", "r221", "r225", "r226", "r227", "r228", "r229", "r230", "r251", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r106", "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r51" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r51" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (decrease) in related party interest payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r51" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "(Increase) decrease in prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsCurrent": { "auth_ref": [ "r1" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.", "label": "Intangible assets" } } }, "localname": "IntangibleAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r39", "r83", "r232", "r234", "r289" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r46", "r136", "r138", "r141", "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r288" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest income" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r56", "r88", "r99", "r118", "r119", "r120", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r212", "r215", "r216", "r223", "r256", "r257" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r56", "r99", "r223", "r258", "r284", "r295" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r26", "r56", "r99", "r118", "r119", "r120", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r212", "r215", "r216", "r223", "r256", "r257", "r258" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Current liability", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r49", "r50", "r53" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r34", "r35", "r38", "r41", "r53", "r56", "r65", "r67", "r68", "r69", "r70", "r72", "r73", "r75", "r84", "r86", "r89", "r92", "r94", "r99", "r118", "r119", "r120", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r222", "r223", "r287", "r299" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Loss available to common stockholders'" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails", "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations", "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r21", "r57", "r254" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Convertible promissory note to related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses, net" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r84", "r86", "r89", "r92", "r94" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r244" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liability - current", "verboseLabel": "Current maturities of operating lease" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets", "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r245", "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amount included in the measurement of lease liabilities for operating lease" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r243" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of Use Asset", "verboseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets", "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted Average remaining lease term (in years):" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://renovacareinc.com/role/LeasesDetails1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r238", "r240" ], "calculation": { "http://renovacareinc.com/role/LeasesDetails1": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r117", "r237", "r238", "r239", "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "Schedule of supplemental lease information" } } }, "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r61", "r74", "r80", "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Basis of Presentation, Organization, Going Concern, Recent Accounting Standards and Earnings (Loss) Per Share" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r10" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r300" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "verboseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r19", "r102" ], "calculation": { "http://renovacareinc.com/role/PrepaidExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other prepaid costs" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r143" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r143" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r258" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r19", "r101", "r102" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://renovacareinc.com/role/PrepaidExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses", "totalLabel": "Total prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets", "http://renovacareinc.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r47" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from the issuance of a related party convertible promissory note" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r34", "r35", "r38", "r48", "r56", "r65", "r72", "r73", "r84", "r86", "r89", "r92", "r94", "r99", "r118", "r119", "r120", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r210", "r213", "r214", "r217", "r218", "r222", "r223", "r290" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r105", "r258", "r291", "r296" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment, net of accumulated depreciation of $15,275 and $12,952, respectively" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r163", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r163", "r252", "r255", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r206", "r269", "r313" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r159", "r258", "r294", "r306", "r307" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative", "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r62", "r63", "r64", "r66", "r71", "r73", "r100", "r203", "r204", "r205", "r207", "r208", "r221", "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r40", "r56", "r81", "r82", "r85", "r90", "r91", "r95", "r96", "r97", "r99", "r118", "r119", "r120", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r223", "r290" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r248", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use asset obtained in exchange for lease obligation" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of accounts payable and accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r164", "r165", "r166", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://renovacareinc.com/role/RelatedPartyConvertiblePromissoryNoteDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of computation of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of future lease payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "verboseLabel": "Prepaid Expenses" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/PrepaidExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r175", "r190", "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r10" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r51" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Expiration" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Shares of Common Stock Issuable from Warrants Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options oustanding - ending balance", "periodStartLabel": "Options outstanding - beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding - ending balance", "periodStartLabel": "Options outstanding - beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Options forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Total" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Options Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contracted term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Options Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/EquityDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r30", "r36", "r37", "r38", "r62", "r63", "r64", "r66", "r71", "r73", "r79", "r100", "r158", "r159", "r203", "r204", "r205", "r207", "r208", "r221", "r225", "r226", "r227", "r228", "r229", "r230", "r251", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r62", "r63", "r64", "r79", "r270" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://renovacareinc.com/role/EquityDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r56", "r98", "r99", "r223", "r258" ], "calculation": { "http://renovacareinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets", "http://renovacareinc.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r55", "r144", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r159", "r161", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r231", "r260" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r231", "r260" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r231", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r231", "r260" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerSharePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://renovacareinc.com/role/BasisOfPresentationOrganizationGoingConcernRecentAccountingStandardsAndEarningsLossPerShareDetails", "http://renovacareinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org/topic&trid=2208923" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r314": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r315": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r316": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r317": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r318": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r319": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r320": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r321": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r322": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r323": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r324": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r325": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r326": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r327": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r328": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r329": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r330": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r331": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r332": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r333": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r334": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r335": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" } }, "version": "2.1" } ZIP 50 0001171843-22-003647-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-003647-xbrl.zip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end